

Fergus Shanahan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7404207/publications.pdf>

Version: 2024-02-01

731
papers

54,995
citations

1046

113
h-index

1715

213
g-index

1005
all docs

1005
docs citations

1005
times ranked

45408
citing authors

#	ARTICLE	IF	CITATIONS
1	Altered Skin and Gut Microbiome in Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2022, 142, 459-468.e15.	0.7	35
2	Making computed tomography safer for patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 175-182.	1.5	1
3	P493 The synthetic glycan KB295 optimises microbiome composition and function in ulcerative colitis: Results from a proof of principle human study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i458-i458.	1.3	0
4	Colorectal microbiota after removal of colorectal cancer. <i>NAR Cancer</i> , 2022, 4, zcac011.	3.1	5
5	When to suspect contamination rather than colonization – lessons from a putative fetal sheep microbiome. <i>Gut Microbes</i> , 2022, 14, 2005751.	9.8	2
6	The gut microbiome as a modulator of healthy ageing. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 565-584.	17.8	162
7	Metagenomic assembled plasmids of the human microbiome vary across disease cohorts. <i>Scientific Reports</i> , 2022, 12, .	3.3	7
8	Modulation, microbiota and inflammation in the adult CF gut: A prospective study. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 837-843.	0.7	11
9	Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study. <i>Gut</i> , 2021, 70, 499-510.	12.1	127
10	Transplanting Microbes for Irritable Bowels or Irritated Microbes or Both?. <i>Gastroenterology</i> , 2021, 160, 15-17.	1.3	1
11	The Healthy Microbiome – What Is the Definition of a Healthy Gut Microbiome?. <i>Gastroenterology</i> , 2021, 160, 483-494.	1.3	174
12	The effects of sustained fitness improvement on the gut microbiome: A longitudinal, repeated measures case-study approach. <i>Translational Sports Medicine</i> , 2021, 4, 174-192.	1.1	14
13	The fecal mycobiome in patients with Irritable Bowel Syndrome. <i>Scientific Reports</i> , 2021, 11, 124.	3.3	30
14	Changing phenotype of inflammatory bowel disease and neglected metabolic health. <i>Cogent Medicine</i> , 2021, 8, .	0.7	1
15	The gut virome in Irritable Bowel Syndrome differs from that of controls. <i>Gut Microbes</i> , 2021, 13, 1-15.	9.8	36
16	A multicentre analysis of <i>Clostridium difficile</i> in persons with Cystic Fibrosis demonstrates that carriage may be transient and highly variable with respect to strain and level. <i>Journal of Infection</i> , 2021, 82, 363-370.	3.3	4
17	Regulation of CEACAM Family Members by IBD-Associated Triggers in Intestinal Epithelial Cells, Their Correlation to Inflammation and Relevance to IBD Pathogenesis. <i>Frontiers in Immunology</i> , 2021, 12, 655960.	4.8	22
18	The undesirable resilience of the pejorative term ‘castrate-resistant prostate cancer’. <i>Irish Journal of Medical Science</i> , 2021, , 1.	1.5	0

#	ARTICLE	IF	CITATIONS
19	Inflammasome Signaling Regulates the Microbial-Neuroimmune Axis and Visceral Pain in Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8336.	4.1	9
20	A Convolutional Neural Network Deep Learning Model Trained on CD Ulcers Images Accurately Identifies NSAID Ulcers. <i>Frontiers in Medicine</i> , 2021, 8, 656493.	2.6	10
21	Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 747-753.	0.7	30
22	TNF- α synergises with IFN- γ to induce caspase-8/JAK1/2-STAT1-dependent death of intestinal epithelial cells. <i>Cell Death and Disease</i> , 2021, 12, 864.	6.3	54
23	244 MICROBIOME ANALYSIS OF UPPER DIGESTIVE TRACT BIOPSY SAMPLES FROM INDIVIDUALS ALONG THE METAPLASIA-DYSPLASIA-ADENOCARCINOMA SEQUENCE.. <i>Ecological Management and Restoration</i> , 2021, 34, .	0.4	0
24	The effect of immunosuppression on patch testing: A cross-sectional study in patients with inflammatory bowel disease. <i>Contact Dermatitis</i> , 2021, 85, 86-88.	1.4	1
25	Mapping the colorectal tumor microbiota. <i>Gut Microbes</i> , 2021, 13, 1-10.	9.8	10
26	Macronutrients, microbiome and precision nutrition. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 145-151.	2.3	7
27	Infographic. Athlete health and performance: no guts no glory. <i>British Journal of Sports Medicine</i> , 2020, 54, 250-250.	6.7	1
28	Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption. <i>Gastroenterology</i> , 2020, 158, 1016-1028.e8.	1.3	122
29	Impaired cognitive function in Crohn's disease: Relationship to disease activity. <i>Brain, Behavior, & Immunity - Health</i> , 2020, 5, 100093.	2.5	11
30	Investigating the Role of Diet and Exercise in Gut Microbe-Host Cometabolism. <i>MSystems</i> , 2020, 5, .	3.8	11
31	Intranasal <i>Bifidobacterium longum</i> protects against viral-induced lung inflammation and injury in a murine model of lethal influenza infection. <i>EBioMedicine</i> , 2020, 60, 102981.	6.1	47
32	Microbiome alterations in IBS. <i>Gut</i> , 2020, 69, 2263-2264.	12.1	10
33	Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease. <i>Nature Communications</i> , 2020, 11, 1512.	12.8	167
34	Microbiome and health implications for ethnic minorities after enforced lifestyle changes. <i>Nature Medicine</i> , 2020, 26, 1089-1095.	30.7	48
35	Mutagenesis by Microbe: the Role of the Microbiota in Shaping the Cancer Genome. <i>Trends in Cancer</i> , 2020, 6, 277-287.	7.4	45
36	Establishing or Exaggerating Causality for the Gut Microbiome: Lessons from Human Microbiota-Associated Rodents. <i>Cell</i> , 2020, 180, 221-232.	28.9	318

#	ARTICLE	IF	CITATIONS
37	Human BCL-G regulates secretion of inflammatory chemokines but is dispensable for induction of apoptosis by IFN- β and TNF- α in intestinal epithelial cells. <i>Cell Death and Disease</i> , 2020, 11, 68.	6.3	18
38	Piphillin predicts metagenomic composition and dynamics from DADA2-corrected 16S rDNA sequences. <i>BMC Genomics</i> , 2020, 21, 56.	2.8	54
39	Defining gastrointestinal transit time using video capsule endoscopy: a study of healthy subjects. <i>Endoscopy International Open</i> , 2020, 08, E396-E400.	1.8	21
40	Encapsulated cyclosporine does not change the composition of the human microbiota when assessed ex vivo and in vivo. <i>Journal of Medical Microbiology</i> , 2020, 69, 854-863.	1.8	12
41	Gut microbiota alterations associated with reduced bone mineral density in older adults. <i>Rheumatology</i> , 2019, 58, 2295-2304.	1.9	106
42	Host Microbiota Regulates Central Nervous System Serotonin Receptor 2C Editing in Rodents. <i>ACS Chemical Neuroscience</i> , 2019, 10, 3953-3960.	3.5	8
43	Faecal microbiota transplantation (FMT): classical bedside-to-bench clinical research. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2019, , .	0.5	1
44	<i>Bifidobacterium breve</i> Bif195 Protects Against Small-Intestinal Damage Caused by Acetylsalicylic Acid in Healthy Volunteers. <i>Gastroenterology</i> , 2019, 157, 637-646.e4.	1.3	50
45	Friendship in medicine: the Corrigan Club considers its demise. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2019, , .	0.5	0
46	Translating the gut microbiome: ready for the clinic?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 656-661.	17.8	33
47	Language, numeracy and logic in microbiome science. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 387-388.	17.8	29
48	Four men in a boat: Ultra-endurance exercise alters the gut microbiome. <i>Journal of Science and Medicine in Sport</i> , 2019, 22, 1059-1064.	1.3	69
49	Letter: dietary fibre benefits for the oesophagusâ€”physical rather than metabolic action? Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1368-1369.	3.7	3
50	Moderate-intensity aerobic and resistance exercise is safe and favorably influences body composition in patients with quiescent Inflammatory Bowel Disease: a randomized controlled cross-over trial. <i>BMC Gastroenterology</i> , 2019, 19, 29.	2.0	47
51	Review article: dietary fibre in the era of microbiome science. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 506-515.	3.7	97
52	The effect of a probiotic blend on gastrointestinal symptoms in constipated patients: a double blind, randomised, placebo controlled 2-week trial. <i>Beneficial Microbes</i> , 2019, 10, 617-627.	2.4	22
53	The Gut Microbiota in Causation, Detection, and Treatment of Cancer. <i>American Journal of Gastroenterology</i> , 2019, 114, 1036-1042.	0.4	25
54	Low-dose CT imaging of the acute abdomen using model-based iterative reconstruction: a prospective study. <i>Emergency Radiology</i> , 2019, 26, 169-177.	1.8	15

#	ARTICLE	IF	CITATIONS
55	A Bifidobacterial pilus-associated protein promotes colonic epithelial proliferation. <i>Molecular Microbiology</i> , 2019, 111, 287-301.	2.5	62
56	How to swim with sharks: a perspective on Voltaire Cousteau's primer. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2019, 112, 61-62.	0.5	0
57	The microbiome of professional athletes differs from that of more sedentary subjects in composition and particularly at the functional metabolic level. <i>Gut</i> , 2018, 67, gutjnl-2016-313627.	12.1	333
58	Tumour-associated and non-tumour-associated microbiota: Addendum. <i>Gut Microbes</i> , 2018, 9, 1-5.	9.8	25
59	Enterotypes in the landscape of gut microbial community composition. <i>Nature Microbiology</i> , 2018, 3, 8-16.	13.3	717
60	Inclusion of the Mesentery in Ileocolic Resection for Crohn's Disease is Associated With Reduced Surgical Recurrence. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1139-1150.	1.3	223
61	A Prospective Metagenomic and Metabolomic Analysis of the Impact of Exercise and/or Whey Protein Supplementation on the Gut Microbiome of Sedentary Adults. <i>MSystems</i> , 2018, 3, .	3.8	148
62	The microbiome regulates amygdala-dependent fear recall. <i>Molecular Psychiatry</i> , 2018, 23, 1134-1144.	7.9	146
63	GREB1 genetic variants are associated with bone mineral density in Caucasians. <i>Journal of Bone and Mineral Metabolism</i> , 2018, 36, 189-199.	2.7	10
64	Determinants of Reduced Genetic Capacity for Butyrate Synthesis by the Gut Microbiome in Crohn's Disease and Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 204-216.	1.3	93
65	CORK Study in Cystic Fibrosis. <i>Chest</i> , 2018, 153, 395-403.	0.8	74
66	The oral microbiota in colorectal cancer is distinctive and predictive. <i>Gut</i> , 2018, 67, 1454-1463.	12.1	425
67	Visualising Bacterial Colonization Dynamics Inside the Gut Using Upconverting Nanoparticles Luminescence Imaging. , 2018, , .		0
68	Dietary Fiber and Gastrointestinal Disease: an Evolving Story. <i>Current Gastroenterology Reports</i> , 2018, 20, 59.	2.5	8
69	The Use of a Mini-Bioreactor Fermentation System as a Reproducible, High-Throughput ex vivo Batch Model of the Distal Colon. <i>Frontiers in Microbiology</i> , 2018, 9, 1844.	3.5	36
70	Changes in microbiota composition, bile and fatty acid metabolism, in successful faecal microbiota transplantation for <i>Clostridioides difficile</i> infection. <i>BMC Gastroenterology</i> , 2018, 18, 131.	2.0	67
71	Social interaction-induced activation of RNA splicing in the amygdala of microbiome-deficient mice. <i>ELife</i> , 2018, 7, .	6.0	73
72	Carbohydrate Syntrophy enhances the establishment of <i>Bifidobacterium breve</i> UCC2003 in the neonatal gut. <i>Scientific Reports</i> , 2018, 8, 10627.	3.3	19

#	ARTICLE	IF	CITATIONS
73	The Gut Microbiota in Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 143-154.	2.2	68
74	Gut microbiota: implications for sports and exercise medicine. <i>British Journal of Sports Medicine</i> , 2017, 51, 700-701.	6.7	31
75	<i>Bifidobacterium breve</i> with $\hat{\pm}$ -linolenic acid alters the composition, distribution and transcription factor activity associated with metabolism and absorption of fat. <i>Scientific Reports</i> , 2017, 7, 43300.	3.3	25
76	The altered gut microbiota in adults with cystic fibrosis. <i>BMC Microbiology</i> , 2017, 17, 58.	3.3	104
77	Tumour-associated and non-tumour-associated microbiota in colorectal cancer. <i>Gut</i> , 2017, 66, 633-643.	12.1	623
78	The effect of exercise interventions on inflammatory biomarkers in healthy, physically inactive subjects: a systematic review. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2017, 110, 629-637.	0.5	46
79	<i>Clostridium difficile</i> carriage in adult cystic fibrosis (CF); implications for patients with CF and the potential for transmission of nosocomial infection. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 291-298.	0.7	25
80	Mechansims Underpinning Successful Faecal Microbiota Transplantation (FMT) for Recurrent <i>Clostridium Difficile</i> Infection. <i>Gastroenterology</i> , 2017, 152, S47-S48.	1.3	0
81	The influence of rosuvastatin on the gastrointestinal microbiota and host gene expression profiles. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, G488-G497.	3.4	43
82	Microbiome and metabolome modifying effects of several cardiovascular disease interventions in apo-E $\hat{\sim}$ / $\hat{\sim}$ mice. <i>Microbiome</i> , 2017, 5, 30.	11.1	83
83	Microbial regulation of hippocampal miRNA expression: Implications for transcription of kynurenine pathway enzymes. <i>Behavioural Brain Research</i> , 2017, 334, 50-54.	2.2	44
84	A pilot study demonstrating the altered gut microbiota functionality in stable adults with Cystic Fibrosis. <i>Scientific Reports</i> , 2017, 7, 6685.	3.3	35
85	Editorial: probiotics in inflammatory bowel disease $\hat{\sim}$ ”wrong organisms, wrong disease, or flawed concepts?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 632-633.	3.7	3
86	Feeding the microbiota: transducer of nutrient signals for the host. <i>Gut</i> , 2017, 66, 1709-1717.	12.1	124
87	A randomised, double-blind, placebo-controlled clinical study: the effects of a synbiotic, Lepicol, in adults with chronic, functional constipation. <i>International Journal of Food Sciences and Nutrition</i> , 2017, 68, 366-377.	2.8	19
88	Quantitative analysis of mucosal oxygenation using ex vivo imaging of healthy and inflamed mammalian colon tissue. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 141-151.	5.4	19
89	Microbiota regulates visceral pain in the mouse. <i>ELife</i> , 2017, 6, .	6.0	117
90	Microbial regulation of microRNA expression in the amygdala and prefrontal cortex. <i>Microbiome</i> , 2017, 5, 102.	11.1	133

#	ARTICLE	IF	CITATIONS
91	Translating Microbiome Science to Societyâ€™s Next?. , 2016, , 465-470.		2
92	Colon: anatomy and structural anomalies. , 2016, , 24-29.		0
93	The Changing Phenotype of Inflammatory Bowel Disease. Gastroenterology Research and Practice, 2016, 2016, 1-9.	1.5	13
94	Laparoscopy and Laparotomy. , 2016, , 698-701.		1
95	Tumors of the Biliary Tract. , 2016, , 368-373.		1
96	Capsule and Small Bowel Endoscopy. , 2016, , 621-625.		0
97	Tumors of the Stomach. , 2016, , 149-152.		0
98	Miscellaneous Diseases of the Stomach. , 2016, , 153-156.		1
99	Zollinger-Ellison Syndrome. , 2016, , 135-139.		1
100	Unconjugated Bile Acids Influence Expression of Circadian Genes: A Potential Mechanism for Microbe-Host Crosstalk. PLoS ONE, 2016, 11, e0167319.	2.5	97
101	Adult microbiotaâ€™deficient mice have distinct dendritic morphological changes: differential effects in the amygdala and hippocampus. European Journal of Neuroscience, 2016, 44, 2654-2666.	2.6	263
102	Pure Iterative Reconstruction Improves Image Quality in Computed Tomography of the Abdomen and Pelvis Acquired at Substantially Reduced Radiation Doses in Patients With Active Crohn Disease. Journal of Computer Assisted Tomography, 2016, 40, 225-233.	0.9	7
103	Microbial contributions to chronic inflammation and metabolic disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2016, 19, 257-262.	2.5	19
104	Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and peroxisome proliferator-activated receptor gamma?. Clinical and Experimental Immunology, 2016, 183, 358-368.	2.6	53
105	Regulation of prefrontal cortex myelination by the microbiota. Translational Psychiatry, 2016, 6, e774-e774.	4.8	459
106	Oral Manifestation of Gastrointestinal Diseases. , 2016, , 574-581.		0
107	Short bowel syndrome. , 2016, , 189-201.		0
108	Preparation of a standardised faecal slurry for ex-vivo microbiota studies which reduces inter-individual donor bias. Journal of Microbiological Methods, 2016, 129, 109-116.	1.6	29

#	ARTICLE	IF	CITATIONS
109	Cystic Lesions of the Pancreas. , 2016, , 324-328.		0
110	Chronic Hepatitis B Viral Infection. , 2016, , 387-391.		0
111	Ulcerative Colitis: Clinical Manifestations and Management. , 2016, , 216-224.		1
112	Gastritis and Gastropathy. , 2016, , 140-148.		0
113	Hepatitis C Virus Infection. , 2016, , 392-396.		0
114	Management of Upper Gastrointestinal Hemorrhage Related to Portal Hypertension. , 2016, , 664-674.		0
115	Exercise, fitness, and the gut. Current Opinion in Gastroenterology, 2016, 32, 67-73.	2.3	37
116	Su1939 Neuro-Immune Changes in IBS: A Link Between Microbiota, TLRs and Sensory-Related Markers?. Gastroenterology, 2016, 150, S594.	1.3	0
117	260 Alterations in the Microbiota in Irritable Bowel Syndrome; A Comparison of Two Geographically Distinct Cohorts. Gastroenterology, 2016, 150, S63.	1.3	5
118	Time to abandon the hygiene hypothesis: new perspectives on allergic disease, the human microbiome, infectious disease prevention and the role of targeted hygiene. Perspectives in Public Health, 2016, 136, 213-224.	1.6	206
119	IL-36 β expression is elevated in ulcerative colitis and promotes colonic inflammation. Mucosal Immunology, 2016, 9, 1193-1204.	6.0	106
120	In the performing art of medicine: the doctor as actor. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 159-160.	0.5	0
121	Prognostic significance of prospectively detected bone marrow micrometastases in esophagogastric cancer: 10-year follow-up confirms prognostic significance. Cancer Medicine, 2015, 4, 1281-1288.	2.8	6
122	Dietary <i>trans</i> -10, <i>cis</i> -12-conjugated linoleic acid alters fatty acid metabolism and microbiota composition in mice. British Journal of Nutrition, 2015, 113, 728-738.	2.3	89
123	Author response: linking lifestyle and microbes. Gut, 2015, 64, 520.1-520.	12.1	2
124	Model-Based Iterative Reconstruction in CT Enterography. American Journal of Roentgenology, 2015, 205, 1173-1181.	2.2	17
125	Adult Hippocampal Neurogenesis Is Regulated by the Microbiome. Biological Psychiatry, 2015, 78, e7-e9.	1.3	363
126	Spatial variation of the colonic microbiota in patients with ulcerative colitis and control volunteers. Gut, 2015, 64, 1553-1561.	12.1	226

#	ARTICLE	IF	CITATIONS
127	Microbes & neurodevelopment – Absence of microbiota during early life increases activity-related transcriptional pathways in the amygdala. <i>Brain, Behavior, and Immunity</i> , 2015, 50, 209-220.	4.1	210
128	The role of pure iterative reconstruction in conventional dose CT enterography. <i>Abdominal Imaging</i> , 2015, 40, 251-257.	2.0	13
129	Separating the microbiome from the hyperbolome. <i>Genome Medicine</i> , 2015, 7, 17.	8.2	12
130	Changing the narrative on antibiotics. <i>Gut</i> , 2015, 64, 1674-1675.	12.1	5
131	Exercise and the microbiota. <i>Gut Microbes</i> , 2015, 6, 131-136.	9.8	127
132	The small bowel microbiota. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 130-136.	2.3	23
133	How the Irish savoured gastroenterology. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 89-91.	2.3	2
134	The microbiota in inflammatory bowel disease. <i>Journal of Gastroenterology</i> , 2015, 50, 495-507.	5.1	196
135	Impact of probiotics in women with gestational diabetes mellitus on metabolic health: a randomized controlled trial. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 496.e1-496.e11.	1.3	90
136	The metabolic role of the microbiota. <i>Clinical Liver Disease</i> , 2015, 5, 91-93.	2.1	2
137	32: Impact of probiotics in women with gestational diabetes mellitus on metabolic health: a randomized controlled trial. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, S22.	1.3	8
138	Fiber man meets microbial man. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 1-2.	4.7	26
139	Concomitant Exposure to Ovalbumin and Endotoxin Augments Airway Inflammation but Not Airway Hyperresponsiveness in a Murine Model of Asthma. <i>PLoS ONE</i> , 2014, 9, e98648.	2.5	20
140	The utilisation and diagnostic yield of radiological imaging in a specialist functional GI disorder clinic: an 11-year retrospective study. <i>European Radiology</i> , 2014, 24, 3097-3104.	4.5	2
141	Identification of a Unique Hybrid Macrophage-Polarization State following Recovery from Lipopolysaccharide Tolerance. <i>Journal of Immunology</i> , 2014, 192, 427-436.	0.8	62
142	Bacterial bile salt hydrolase in host metabolism: Potential for influencing gastrointestinal microbe-host crosstalk. <i>Gut Microbes</i> , 2014, 5, 669-674.	9.8	99
143	Selective influence of host microbiota on cAMP-mediated ion transport in mouse colon. <i>Neurogastroenterology and Motility</i> , 2014, 26, 887-890.	3.0	37
144	PPO.19 – Probiotics in obese pregnancy to reduce maternal fasting glucose: A randomised controlled trial. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2014, 99, A156.1-A156.	2.8	5

#	ARTICLE	IF	CITATIONS
145	The impact of probiotics in obese pregnancy to reduce maternal fasting glucose: A randomized controlled trial. <i>Proceedings of the Nutrition Society</i> , 2014, 73, .	1.0	1
146	Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease. <i>British Journal of Nutrition</i> , 2014, 112, 1163-1174.	2.3	19
147	Gastric digestion of α -lactalbumin in adult human subjects using capsule endoscopy and nasogastric tube sampling. <i>British Journal of Nutrition</i> , 2014, 112, 638-646.	2.3	21
148	The sustained trajectory of small bowel research. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 117-119.	2.3	0
149	Cognitive performance in irritable bowel syndrome: evidence of a stress-related impairment in visuospatial memory. <i>Psychological Medicine</i> , 2014, 44, 1553-1566.	4.5	88
150	Detection of <i>Mycobacterium avium</i> subspecies paratuberculosis in patients with Crohn's disease is unrelated to the presence of single nucleotide polymorphisms rs2241880 (ATG16L1) and rs10045431 (IL12B). <i>Medical Microbiology and Immunology</i> , 2014, 203, 195-205.	4.8	8
151	Manipulation of the Microbiota for Treatment of IBS and IBD—Challenges and Controversies. <i>Gastroenterology</i> , 2014, 146, 1554-1563.	1.3	149
152	Probiotics in obese pregnancy do not reduce maternal fasting glucose: a double-blind, placebo-controlled, randomized trial (Probiotics in Pregnancy Study). <i>American Journal of Clinical Nutrition</i> , 2014, 99, 1432-1439.	4.7	135
153	Gut microbiota modulation and implications for host health: Dietary strategies to influence the gut-brain axis. <i>Innovative Food Science and Emerging Technologies</i> , 2014, 22, 239-247.	5.6	50
154	Bioavailability of the anti-clostridial bacteriocin thuricin CD in gastrointestinal tract. <i>Microbiology (United Kingdom)</i> , 2014, 160, 439-445.	1.8	38
155	Editorial: probiotics and IBS—where are we now?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 318-318.	3.7	2
156	Exopolysaccharide-Producing Probiotic Lactobacilli Reduce Serum Cholesterol and Modify Enteric Microbiota in ApoE-Deficient Mice. <i>Journal of Nutrition</i> , 2014, 144, 1956-1962.	2.9	80
157	Microbiota is essential for social development in the mouse. <i>Molecular Psychiatry</i> , 2014, 19, 146-148.	7.9	708
158	The Future of Probiotics for Disorders of the Brain-Gut Axis. <i>Advances in Experimental Medicine and Biology</i> , 2014, 817, 417-432.	1.6	14
159	Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 7421-7426.	7.1	471
160	P.1.c.004 The microbiota-gut-brain axis regulates adult hippocampal neurogenesis. <i>European Neuropsychopharmacology</i> , 2014, 24, S183.	0.7	0
161	Disturbance of the gut microbiota in early-life selectively affects visceral pain in adulthood without impacting cognitive or anxiety-related behaviors in male rats. <i>Neuroscience</i> , 2014, 277, 885-901.	2.3	222
162	Gut microbiota and obesity: Role in aetiology and potential therapeutic target. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 585-597.	2.4	92

#	ARTICLE	IF	CITATIONS
163	Ethereal and material gain: unanticipated opportunity with illness or disability. <i>Clinical Medicine</i> , 2014, 14, 44-46.	1.9	0
164	Host-microbe interactions and spatial variation of cancer in the gut. <i>Nature Reviews Cancer</i> , 2014, 14, 511-512.	28.4	16
165	DOP017 Dysbiosis in ulcerative colitis: adding the spatial component. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S22.	1.3	0
166	Exercise and associated dietary extremes impact on gut microbial diversity. <i>Gut</i> , 2014, 63, 1913-1920.	12.1	987
167	The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. <i>Molecular Psychiatry</i> , 2013, 18, 666-673.	7.9	1,445
168	Bcl-3 deficiency protects against dextran-sodium sulphate-induced colitis in the mouse. <i>Clinical and Experimental Immunology</i> , 2013, 173, 332-342.	2.6	20
169	Pellino3 ubiquitinates RIP2 and mediates Nod2-induced signaling and protective effects in colitis. <i>Nature Immunology</i> , 2013, 14, 927-936.	14.5	83
170	Targeting the EP1 receptor reduces Fas ligand expression and increases the antitumor immune response in an <i>in vivo</i> model of colon cancer. <i>International Journal of Cancer</i> , 2013, 133, 825-834.	5.1	21
171	Effects of the Intestinal Microbiota on Behavior and Brain Biochemistry. <i>World Review of Nutrition and Dietetics</i> , 2013, , 56-63.	0.3	0
172	A prospective feasibility study of sub-millisievert abdominopelvic CT using iterative reconstruction in Crohn's disease. <i>European Radiology</i> , 2013, 23, 2503-2512.	4.5	42
173	The Neglected Spectrum of Diverticular-related Disorders. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1620-1621.	4.4	3
174	Identification of TLR10 as a Key Mediator of the Inflammatory Response to <i>Listeria monocytogenes</i> in Intestinal Epithelial Cells and Macrophages. <i>Journal of Immunology</i> , 2013, 191, 6084-6092.	0.8	99
175	Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. <i>Gut</i> , 2013, 62, 220-226.	12.1	235
176	Gene silencing of TNF-alpha in a murine model of acute colitis using a modified cyclodextrin delivery system. <i>Journal of Controlled Release</i> , 2013, 168, 28-34.	9.9	61
177	<i>Bifidobacterium infantis</i> suppression of Peyer's patch MIP-1 α and MIP-1 β secretion during <i>Salmonella</i> infection correlates with increased local CD4+CD25+ T cell numbers. <i>Cellular Immunology</i> , 2013, 281, 134-140.	3.0	37
178	Natural killer cells protect mice from DSS-induced colitis by regulating neutrophil function via the NKG2A receptor. <i>Mucosal Immunology</i> , 2013, 6, 1016-1026.	6.0	55
179	TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNF α , from CD3+CD161+ T cells to exacerbate gut inflammation. <i>Mucosal Immunology</i> , 2013, 6, 886-899.	6.0	59
180	Phylogenetic Analysis of Dysbiosis in Ulcerative Colitis During Remission. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 481-488.	1.9	285

#	ARTICLE	IF	CITATIONS
181	In praise of the literary eponym–Henry V sign. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 93-94.	0.5	1
182	CROHN'S DISEASE: HAS THE PHENOTYPE CHANGED?. Gut, 2013, 62, A22.1-A22.	12.1	0
183	Digestion of epithelial tight junction proteins by the commensal <i>Clostridium perfringens</i> . American Journal of Physiology - Renal Physiology, 2013, 305, G740-G748.	3.4	19
184	Antimicrobials. Gut Microbes, 2013, 4, 48-53.	9.8	24
185	A Randomized Controlled Study of Mesalamine After Acute Diverticulitis. Journal of Clinical Gastroenterology, 2013, 47, 621-629.	2.2	110
186	The colonic microbiota in health and disease. Current Opinion in Gastroenterology, 2013, 29, 49-54.	2.3	81
187	Natural Killer Cells Protect against Mucosal and Systemic Infection with the Enteric Pathogen <i>Citrobacter rodentium</i> . Infection and Immunity, 2013, 81, 460-469.	2.2	53
188	Risk factors for hand injury in hurling: a cross-sectional study. BMJ Open, 2013, 3, e002634.	1.9	6
189	<i>Bifidobacterium infantis</i> 35624 modulates host inflammatory processes beyond the gut. Gut Microbes, 2013, 4, 325-339.	9.8	342
190	Prevalence and characterization of <i>Clostridium perfringens</i> from the faecal microbiota of elderly Irish subjects. Journal of Medical Microbiology, 2013, 62, 457-466.	1.8	42
191	Movers and shakers. Gut Microbes, 2013, 4, 4-16.	9.8	236
192	THU0014...Association between a polymorphism in the fractalkine receptor, CX3CR1, and rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 71, 158.2-158.	0.9	0
193	Targeting the Microbiota to Address Diet-Induced Obesity: A Time Dependent Challenge. PLoS ONE, 2013, 8, e65790.	2.5	132
194	Depth-Dependent Differences in Community Structure of the Human Colonic Microbiota in Health. PLoS ONE, 2013, 8, e78835.	2.5	21
195	Crohn's Disease: Minimizing Radiation Dose. , 2013, , 671-676.		0
196	Microbes and metabolic health. Gut, 2012, 61, 1655-1656.	12.1	4
197	Shining a Light on Intestinal Traffic. Clinical and Developmental Immunology, 2012, 2012, 1-14.	3.3	8
198	Bacteriophages ϕ MR299-2 and ϕ NH-4 Can Eliminate <i>Pseudomonas aeruginosa</i> in the Murine Lung and on Cystic Fibrosis Lung Airway Cells. MBio, 2012, 3, e00029-12.	4.1	218

#	ARTICLE	IF	CITATIONS
199	Role of Radiologic Imaging in Irritable Bowel Syndrome: Evidence-based Review. <i>Radiology</i> , 2012, 262, 485-494.	7.3	32
200	In Search of Lost Opportunities: Marcel Proyce and James Joust Discuss Doctors, Diseases, Life and Death (a Hypothetical Conversation between Marcel Proust and James Joyce). <i>Perspectives in Biology and Medicine</i> , 2012, 55, 155-161.	0.5	1
201	Portrait of an immunoregulatory bifidobacterium. <i>Gut Microbes</i> , 2012, 3, 261-266.	9.8	104
202	<i>Bifidobacterium infantis</i> 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. <i>Gut</i> , 2012, 61, 354-366.	12.1	242
203	The gut microbiota and its relationship to diet and obesity. <i>Gut Microbes</i> , 2012, 3, 186-202.	9.8	382
204	Shanahan's Response to Hayman Regarding Darwinian Dyspepsia. <i>American Journal of Gastroenterology</i> , 2012, 107, 1588.	0.4	0
205	<i>Bifidobacterium Infantis</i> 35624 Protects Against Salmonella -Induced Reductions in Digestive Enzyme Activity in Mice by Attenuation of the Host Inflammatory Response. <i>Clinical and Translational Gastroenterology</i> , 2012, 3, e15.	2.5	40
206	Darwinian Dyspepsia: An Extraordinary Scientist, an Ordinary Illness, Great Dignity. <i>American Journal of Gastroenterology</i> , 2012, 107, 161-164.	0.4	12
207	Carriage of <i>Clostridium difficile</i> in outpatients with irritable bowel syndrome. <i>Journal of Medical Microbiology</i> , 2012, 61, 1290-1294.	1.8	15
208	Minimization of Radiation Exposure due to Computed Tomography in Inflammatory Bowel Disease. <i>ISRN Gastroenterology</i> , 2012, 2012, 1-7.	1.5	14
209	The Sphingosine-1-Phosphate Analogue FTY720 Impairs Mucosal Immunity and Clearance of the Enteric Pathogen <i>Citrobacter rodentium</i> . <i>Infection and Immunity</i> , 2012, 80, 2712-2723.	2.2	23
210	Radiologic Imaging in Cystic Fibrosis. <i>Chest</i> , 2012, 141, 1575-1583.	0.8	76
211	World Gastroenterology Organisation Global Guidelines. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 468-481.	2.2	321
212	The microbiota in inflammatory bowel disease: friend, bystander, and sometime-villain. <i>Nutrition Reviews</i> , 2012, 70, S31-S37.	5.8	34
213	Translating the microbiota to medicine. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 72-74.	17.8	27
214	Influence of gut microbiota and manipulation by probiotics and prebiotics on host tissue fat: Potential clinical implications. <i>Lipid Technology</i> , 2012, 24, 227-229.	0.3	1
215	Increased Risk of Miscarriage and Ectopic Pregnancy Among Women With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 902-909.	4.4	20
216	Contrasting effects of <i>Bifidobacterium breve</i> NCIMB 702258 and <i>Bifidobacterium breve</i> DPC 6330 on the composition of murine brain fatty acids and gut microbiota. <i>American Journal of Clinical Nutrition</i> , 2012, 95, 1278-1287.	4.7	109

#	ARTICLE	IF	CITATIONS
217	Diagnostic Accuracy of Computed Tomography Using Lower Doses of Radiation for Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 886-892.	4.4	45
218	Probiotics in Transition. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1220-1224.	4.4	33
219	Immunomodulatory effects of feeding with <i>Bifidobacterium longum</i> on allergen-induced lung inflammation in the mouse. <i>Pulmonary Pharmacology and Therapeutics</i> , 2012, 25, 325-334.	2.6	29
220	Mechanism of protection of transepithelial barrier function by <i>Lactobacillus salivarius</i> : strain dependence and attenuation by bacteriocin production. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, G1029-G1041.	3.4	75
221	The Colonic Microbiota and Colonic Disease. <i>Current Gastroenterology Reports</i> , 2012, 14, 446-452.	2.5	22
222	Categorization of the gut microbiota: enterotypes or gradients?. <i>Nature Reviews Microbiology</i> , 2012, 10, 591-592.	28.6	260
223	Plain abdominal radiographs in patients with Crohn's disease: Radiological findings and diagnostic value. <i>Clinical Radiology</i> , 2012, 67, 774-781.	1.1	10
224	The gut microbiota—a clinical perspective on lessons learned. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 609-614.	17.8	92
225	<i>Bifidobacterium</i> surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2108-2113.	7.1	450
226	Radiation Exposure From Diagnostic Imaging Among Patients With Gastrointestinal Disorders. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 259-265.	4.4	40
227	Selection of Symptomatic Patients with Crohn's Disease for Abdominopelvic Computed Tomography: Role of Serum C-Reactive Protein. <i>Canadian Association of Radiologists Journal</i> , 2012, 63, 267-274.	2.0	7
228	A Commentary on the Safety of Probiotics. <i>Gastroenterology Clinics of North America</i> , 2012, 41, 869-876.	2.2	56
229	<i>Bifidobacterium breve</i> with \pm -Linolenic Acid and Linoleic Acid Alters Fatty Acid Metabolism in the Maternal Separation Model of Irritable Bowel Syndrome. <i>PLoS ONE</i> , 2012, 7, e48159.	2.5	30
230	Computed Tomography Assessment of Intestinal Gas Volumes in Functional Gastrointestinal Disorders. <i>Journal of Neurogastroenterology and Motility</i> , 2012, 18, 419-425.	2.4	10
231	Gut microbiota composition correlates with diet and health in the elderly. <i>Nature</i> , 2012, 488, 178-184.	27.8	2,618
232	<i>Clostridium difficile</i> Carriage in Elderly Subjects and Associated Changes in the Intestinal Microbiota. <i>Journal of Clinical Microbiology</i> , 2012, 50, 867-875.	3.9	184
233	Differential intestinal <i>M</i> cell gene expression response to gut commensals. <i>Immunology</i> , 2012, 136, 312-324.	4.4	20
234	CT-based estimation of intracavitary gas volumes using threshold-based segmentation: In vitro study to determine the optimal threshold range. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012, 56, 289-294.	1.8	8

#	ARTICLE	IF	CITATIONS
235	Managing chronic disease in Ireland: hospital admission rates and clinical outcomes in a large ulcerative colitis population. <i>Irish Journal of Medical Science</i> , 2012, 181, 65-71.	1.5	7
236	Perplexing plain abdominal x-ray. <i>Gut</i> , 2011, 60, 218-218.	12.1	2
237	Differential Expression of Toll-Like Receptors in Patients With Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2011, 106, 329-336.	0.4	178
238	The Immunomodulatory Drug FTY720 Prevents Clearance of <i>Citrobacter rodentium</i> Infection in Mice. <i>Gastroenterology</i> , 2011, 140, S-325.	1.3	0
239	<i>Enterococcus faecalis</i> Metalloprotease Compromises Epithelial Barrier and Contributes to Intestinal Inflammation. <i>Gastroenterology</i> , 2011, 141, 959-971.	1.3	246
240	Minimization of radiation exposure due to computed tomography in inflammatory bowel disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 105-110.	1.5	12
241	MiR-146a Negatively Regulates IL-17A Inflammatory Response and is Elevated in Intestinal Epithelial Cells From Inflammatory Bowel Disease (IBD) Patients. <i>Gastroenterology</i> , 2011, 140, S-84.	1.3	1
242	Stimulation of T-Cells in Irritable Bowel Syndrome (IBS) Mucosal Biopsy Tissue Releases Cytokines Which Selectively Activate Submucosal Neurons. <i>Gastroenterology</i> , 2011, 140, S-129.	1.3	0
243	The colonic microflora and probiotic therapy in health and disease. <i>Current Opinion in Gastroenterology</i> , 2011, 27, 61-65.	2.3	22
244	The effect of vitamin K1 supplementation for 12 months on bone mineral density and indices of vitamin K status and bone turnover in adult Crohn's disease patients. <i>Proceedings of the Nutrition Society</i> , 2011, 70, .	1.0	0
245	Increased health burden associated with <i>Clostridium difficile</i> diarrhoea in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 394-395.	3.7	2
246	Induction and Activation of Adaptive Immune Populations During Acute and Chronic Phases of a Murine Model of Experimental Colitis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 79-89.	2.3	88
247	Small Intestinal Bacterial Overgrowth in Nonalcoholic Steatohepatitis: Association with Toll-Like Receptor 4 Expression and Plasma Levels of Interleukin 8. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1524-1534.	2.3	165
248	Biochemical and metabolomic phenotyping in the identification of a vitamin D responsive metabotype for markers of the metabolic syndrome. <i>Molecular Nutrition and Food Research</i> , 2011, 55, 679-690.	3.3	84
249	Degradation of the extracellular matrix components by bacterial-derived metalloproteases. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1189-1200.	1.9	60
250	Molecular mechanisms of probiotic action: it's all in the strains!. <i>Gut</i> , 2011, 60, 1026-1027.	12.1	19
251	Recombinant lactobacilli expressing linoleic acid isomerase can modulate the fatty acid composition of host adipose tissue in mice. <i>Microbiology (United Kingdom)</i> , 2011, 157, 609-615.	1.8	48
252	Who needs doctors? Staying fresh in changing times. <i>Clinical Medicine</i> , 2011, 11, 587-588.	1.9	0

#	ARTICLE	IF	CITATIONS
253	An unusual phenotype in Muckle-Wells syndrome associated with NLRP3 E311K. <i>Rheumatology</i> , 2011, 50, 419-420.	1.9	6
254	The hybrid science of diet, microbes, and metabolic health. <i>American Journal of Clinical Nutrition</i> , 2011, 94, 1-2.	4.7	28
255	Functional genome analysis of <i>Bifidobacterium breve</i> UCC2003 reveals type IVb tight adherence (Tad) pili as an essential and conserved host-colonization factor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 11217-11222.	7.1	328
256	Effect of broad- and narrow-spectrum antimicrobials on <i>Clostridium difficile</i> and microbial diversity in a model of the distal colon. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 4639-4644.	7.1	313
257	Composition, variability, and temporal stability of the intestinal microbiota of the elderly. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 4586-4591.	7.1	1,418
258	Response to Sprakes et al.. <i>American Journal of Gastroenterology</i> , 2011, 106, 166-167.	0.4	0
259	Oral Administration of the Probiotic <i>Bifidobacterium Infantis</i> 35624 to Humans Induces Immunoregulatory Responses In Vivo. <i>American Journal of Gastroenterology</i> , 2011, 106, S463-S464.	0.4	0
260	Complementary Human mDC and pDC Mechanisms Ensure Induction of Foxp3+ T Cells in Response to the Commensal Microbiota. <i>American Journal of Gastroenterology</i> , 2011, 106, S478.	0.4	0
261	Investigating physiological variation in healthy Irish adults using a combination of traditional techniques and emerging metabolomic technologies. <i>Proceedings of the Nutrition Society</i> , 2010, 69, .	1.0	0
262	The effects of probiotic supplementation on gut microbiota composition, immunological and biochemical markers in healthy volunteers. <i>Proceedings of the Nutrition Society</i> , 2010, 69, .	1.0	1
263	Impact of Administered <i>Bifidobacterium</i> on Murine Host Fatty Acid Composition. <i>Lipids</i> , 2010, 45, 429-436.	1.7	63
264	Asymptomatic carriage of <i>Clostridium difficile</i> in an Irish continuing care institution for the elderly: prevalence and characteristics. <i>Irish Journal of Medical Science</i> , 2010, 179, 245-250.	1.5	35
265	A Molecular Analysis of Fecal and Mucosal Bacterial Communities in Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2010, 55, 392-397.	2.3	228
266	<i>Bifidobacterium animalis</i> AHC7 protects against pathogen-induced NF- κ B activation in vivo. <i>BMC Immunology</i> , 2010, 11, 63.	2.2	33
267	<i>Mycobacterium avium</i> subsp. <i>Paratuberculosis</i> (MAP) as a modifying factor in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 296-304.	1.9	43
268	Differential regulation of Toll-like receptor signalling in spleen and Peyer's patch dendritic cells. <i>Immunology</i> , 2010, 131, 438-448.	4.4	25
269	Bacterial strain-specific induction of Foxp3 ⁺ T regulatory cells is protective in murine allergy models. <i>Clinical and Experimental Allergy</i> , 2010, 40, 811-819.	2.9	189
270	99th Dahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders: Host-microbe interactions in the gut: target for drug therapy, opportunity for drug discovery. <i>Clinical and Experimental Immunology</i> , 2010, 160, 92-97.	2.6	16

#	ARTICLE	IF	CITATIONS
271	Down-regulation of p38 mitogen-activated protein kinase activation and proinflammatory cytokine production by mitogen-activated protein kinase inhibitors in inflammatory bowel disease. <i>Clinical and Experimental Immunology</i> , 2010, 162, 108-115.	2.6	52
272	Use of bioluminescence imaging to track neutrophil migration and its inhibition in experimental colitis. <i>Clinical and Experimental Immunology</i> , 2010, 162, 188-196.	2.6	30
273	Irritable Bowel Syndrome Rates Following Organic Disease of Upper and Lower Gastrointestinal Tract. <i>American Journal of Gastroenterology</i> , 2010, 105, S484-S485.	0.4	1
274	Probiotic Colonization of the Adherent Mucus Layer of HT29MTXE12 Cells Attenuates <i>Campylobacter jejuni</i> Virulence Properties. <i>Infection and Immunity</i> , 2010, 78, 2812-2822.	2.2	81
275	Exercise-induced bronchoconstriction and exercise testing in an international rugby union team. <i>Thorax</i> , 2010, 65, 843-844.	5.6	4
276	Technical Advance: Function and efficacy of an $\alpha 4$ -integrin antagonist using bioluminescence imaging to detect leukocyte trafficking in murine experimental colitis. <i>Journal of Leukocyte Biology</i> , 2010, 88, 1271-1278.	3.3	14
277	IBS: an epigenetic perspective. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 465-471.	17.8	75
278	Response to Andrews et al.. <i>American Journal of Gastroenterology</i> , 2010, 105, 2703-2704.	0.4	0
279	Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders, from Rationale to Reality. <i>Gastroenterology Clinics of North America</i> , 2010, 39, 721-726.	2.2	36
280	Probiotics in Perspective. <i>Gastroenterology</i> , 2010, 139, 1808-1812.	1.3	95
281	Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. <i>Gut</i> , 2010, 59, 1635-1642.	12.1	808
282	Plasma Cytokine Profiles in Females With Irritable Bowel Syndrome and Extra-Intestinal Co-Morbidity. <i>American Journal of Gastroenterology</i> , 2010, 105, 2235-2243.	0.4	146
283	Irritable Bowel Syndrome—Type Symptoms in Patients With Inflammatory Bowel Disease: A Real Association or Reflection of Occult Inflammation?. <i>American Journal of Gastroenterology</i> , 2010, 105, 1789-1794.	0.4	204
284	Gut Microbes: From Bugs to Drugs. <i>American Journal of Gastroenterology</i> , 2010, 105, 275-279.	0.4	48
285	Esophageal intramural pseudodiverticulosis characterized by barium esophagography: a case report. <i>Journal of Medical Case Reports</i> , 2010, 4, 145.	0.8	7
286	Inflammatory bowel disease—From mechanisms to treatment strategies. <i>Autoimmunity</i> , 2010, 43, 463-477.	2.6	44
287	Enteric Microbiota and Small Intestinal Bacterial Overgrowth. , 2010, , 1769-1778.e4.		6
288	Efficacy of Delayed-Release Mesalamine in the Prevention of GI Symptoms Following Acute Diverticulitis: Results of the DIVA Trial. <i>American Journal of Gastroenterology</i> , 2010, 105, S139.	0.4	8

#	ARTICLE	IF	CITATIONS
289	Exploring the Diversity of the Bifidobacterial Population in the Human Intestinal Tract. <i>Applied and Environmental Microbiology</i> , 2009, 75, 1534-1545.	3.1	270
290	The Vexed Relationship Between <i>Clostridium Difficile</i> and Inflammatory Bowel Disease: An Assessment of Carriage in an Outpatient Setting Among Patients in Remission. <i>American Journal of Gastroenterology</i> , 2009, 104, 1162-1169.	0.4	177
291	The emerging role of the microbial-gastrointestinal-neural axis. <i>Gastroenterology Insights</i> , 2009, 1, 3.	1.2	5
292	Sport and recreation-related injuries and fracture occurrence among emergency department attendees: implications for exercise prescription and injury prevention. <i>Emergency Medicine Journal</i> , 2009, 26, 590-595.	1.0	16
293	Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues. <i>American Journal of Clinical Nutrition</i> , 2009, 89, 1393-1401.	4.7	162
294	Loss of vagal anti-inflammatory effect: in vivo visualization and adoptive transfer. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2009, 297, R1118-R1126.	1.8	84
295	The language of medicine: words as servants and scoundrels. <i>Clinical Medicine</i> , 2009, 9, 131-135.	1.9	12
296	Modulation of pathogen-induced CCL20 secretion from HT-29 human intestinal epithelial cells by commensal bacteria. <i>BMC Immunology</i> , 2009, 10, 54.	2.2	50
297	Metabolic activity of probiotics—Oxalate degradation. <i>Veterinary Microbiology</i> , 2009, 136, 100-107.	1.9	43
298	Portrait of a canine probiotic <i>Bifidobacterium</i> —From gut to gut. <i>Veterinary Microbiology</i> , 2009, 139, 106-112.	1.9	38
299	Cogan's syndrome: present and future directions. <i>Rheumatology International</i> , 2009, 29, 1117-1121.	3.0	26
300	Bacterial signalling overrides cytokine signalling and modifies dendritic cell differentiation. <i>Immunology</i> , 2009, 128, e805-15.	4.4	14
301	Involvement of T helper type 17 and regulatory T cell activity in <i>Citrobacter rodentium</i> invasion and inflammatory damage. <i>Clinical and Experimental Immunology</i> , 2009, 157, 148-154.	2.6	55
302	Therapeutic implications of manipulating and mining the microbiota. <i>Journal of Physiology</i> , 2009, 587, 4175-4179.	2.9	40
303	Microbiomic analysis of the bifidobacterial population in the human distal gut. <i>ISME Journal</i> , 2009, 3, 745-751.	9.8	128
304	Culture-independent analysis of desulfovibrios in the human distal colon of healthy, colorectal cancer and polypectomized individuals. <i>FEMS Microbiology Ecology</i> , 2009, 69, 213-221.	2.7	116
305	Evaluation of colostrum-derived human mammary-associated serum amyloid A3 (M-SAA3) protein and peptide derivatives for the prevention of enteric infection: <i>in vitro</i> and in murine models of intestinal disease. <i>FEMS Immunology and Medical Microbiology</i> , 2009, 55, 404-413.	2.7	13
306	Improved fracture prediction when the FRAX® tool is used in combination with vertebral morphometry. <i>Bone</i> , 2009, 44, S390-S391.	2.9	0

#	ARTICLE	IF	CITATIONS
307	Undiagnosed Maternal Celiac Disease in Pregnancy and an Increased Risk of Fetal Growth Restriction. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 792-793.	2.2	8
308	The effect of short-term phylloquinone supplementation on indices of vitamin K status and bone turnover in adult patients with Crohn's disease. <i>Proceedings of the Nutrition Society</i> , 2009, 68, .	1.0	1
309	The evolving epidemiology of inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2009, 25, 301-305.	2.3	89
310	Linking lifestyle with microbiota and risk of chronic inflammatory disorders. , 2009, , 93-102.		1
311	Don't forget increased risk of fetal growth restriction. <i>BMJ: British Medical Journal</i> , 2009, 338, b1069-b1069.	2.3	1
312	A Case of Herpes and Candidal Esophagitis: The Diagnostic Importance of Endoscopy in Odynophagia and Fever. <i>American Journal of Gastroenterology</i> , 2009, 104, S200-S201.	0.4	0
313	High levels of Lymphotoxin-Beta (LT-Beta) gene expression in rheumatoid arthritis synovium: clinical and cytokine correlations. <i>Rheumatology International</i> , 2008, 28, 979-986.	3.0	40
314	Bad language in gastroenterology. <i>Current Gastroenterology Reports</i> , 2008, 10, 91-93.	2.5	1
315	From bugs to drugsâ€”Mining the gut microbiota. <i>Current Gastroenterology Reports</i> , 2008, 10, 515-516.	2.5	1
316	Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. <i>Gut</i> , 2008, 57, 1185-1191.	12.1	239
317	Are patients with IBD knowledgeable about the risks of their medications?. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S70-S71.	1.9	5
318	Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells. <i>British Journal of Cancer</i> , 2008, 99, 502-512.	6.4	35
319	Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. <i>Environmental Microbiology</i> , 2008, 10, 789-798.	3.8	216
320	Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. <i>Environmental Microbiology</i> , 2008, 10, 1382-1382.	3.8	13
321	The CD8+ Leu-7+ subset of T cells in Crohn's disease: distinction between cytotoxic and covert suppressor functions. <i>Clinical and Experimental Immunology</i> , 2008, 80, 387-394.	2.6	9
322	Triggered human mucosal T cells release tumour necrosis factor-alpha and interferon-gamma which kill human colonic epithelial cells. <i>Clinical and Experimental Immunology</i> , 2008, 83, 79-84.	2.6	145
323	Evidence of an enhanced central 5HT response in irritable bowel syndrome and in the rat maternal separation model. <i>Neurogastroenterology and Motility</i> , 2008, 20, 680-688.	3.0	54
324	Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferon-gamma, severity of symptoms and psychiatric comorbidity. <i>Neurogastroenterology and Motility</i> , 2008, 20, 1291-1297.	3.0	108

#	ARTICLE	IF	CITATIONS
325	Human methanogen diversity and incidence in healthy and diseased colonic groups using mcrA gene analysis. BMC Microbiology, 2008, 8, 79.	3.3	158
326	43 The Role of T Cells in Vagal Protection Against Intestinal Inflammation. Gastroenterology, 2008, 134, A-6.	1.3	1
327	Enhanced Cholinergic-Mediated Increase in the Pro-Inflammatory Cytokine IL-6 in Irritable Bowel Syndrome: Role of Muscarinic Receptors. American Journal of Gastroenterology, 2008, 103, 2570-2576.	0.4	122
328	Mucosal cytokine imbalance in irritable bowel syndrome. Scandinavian Journal of Gastroenterology, 2008, 43, 1467-1476.	1.5	150
329	Commensal-Induced Regulatory T Cells Mediate Protection against Pathogen-Stimulated NF- κ B Activation. PLoS Pathogens, 2008, 4, e1000112.	4.7	315
330	Protective effects of <i>Lactobacillus reuteri</i> and <i>Bifidobacterium infantis</i> in murine models for colitis do not involve the vagus nerve. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 295, R1131-R1137.	1.8	61
331	Crohn's disease: factors associated with exposure to high levels of diagnostic radiation. Gut, 2008, 57, 1524-1529.	12.1	307
332	Drug Interactions in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2008, 103, 207-219.	0.4	19
333	Dietary intakes and body composition in adult patients with long-standing Crohn's disease currently in remission. Proceedings of the Nutrition Society, 2008, 67, .	1.0	0
334	James Joyce and gastroenterology. Clinical Medicine, 2008, 8, 632-633.	1.9	4
335	Probiotics, prebiotics, and inflammatory bowel disease. , 2007, , 90-116.		1
336	Antimicrobial activity of lacticin 3147 against clinical Clostridium difficile strains. Journal of Medical Microbiology, 2007, 56, 940-946.	1.8	167
337	Exploring the link between gut microbes and obesity. Future Microbiology, 2007, 2, 261-263.	2.0	0
338	Probiotic Effects on Inflammatory Bowel Disease1,. Journal of Nutrition, 2007, 137, 819S-824S.	2.9	137
339	Intestinal tuberculosis mimicking Crohn's disease: lessons relearned in a new era. European Journal of Gastroenterology and Hepatology, 2007, 19, 347-349.	1.6	22
340	The normal intestinal microbiota. Current Opinion in Infectious Diseases, 2007, 20, 508-513.	3.1	114
341	Gut Microbiota: Mining for Therapeutic Potential. Clinical Gastroenterology and Hepatology, 2007, 5, 274-284.	4.4	116
342	Irritable Bowel Syndrome: Shifting the Focus Toward the Gut Microbiota. Gastroenterology, 2007, 133, 340-342.	1.3	69

#	ARTICLE	IF	CITATIONS
343	The gut microbiota and disease – an inner repository for drug discovery. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2007, 4, 195-200.	0.5	11
344	Rapid and Noninvasive Metabonomic Characterization of Inflammatory Bowel Disease. <i>Journal of Proteome Research</i> , 2007, 6, 546-551.	3.7	539
345	Mechanisms of Action of Probiotics in Intestinal Diseases. <i>Scientific World Journal, The</i> , 2007, 7, 31-46.	2.1	96
346	Mucosal Cytokine Imbalance in Irritable Bowel Syndrome (IBS). <i>American Journal of Gastroenterology</i> , 2007, 102, S514-S515.	0.4	1
347	Preface. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 753-754.	2.4	0
348	In vitro replication models for the hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2007, 14, 2-10.	2.0	18
349	Steroid allergy in patients with inflammatory bowel disease. <i>British Journal of Dermatology</i> , 2007, 157, 967-969.	1.5	20
350	<i>Salmonella typhimurium</i> stimulation combined with tumour-derived heat shock proteins induces potent dendritic cell anti-tumour responses in a murine model. <i>Clinical and Experimental Immunology</i> , 2007, 149, 109-116.	2.6	16
351	Colitis-associated cancer and dysplasia surveillance: An opposing perspective. <i>Current Gastroenterology Reports</i> , 2007, 9, 175-176.	2.5	1
352	Prevalence of 5-ASA Use in Diverticulitis and Diverticulosis by Age and Gender. <i>American Journal of Gastroenterology</i> , 2007, 102, S251.	0.4	0
353	Probiotics in Inflammatory Bowel Disease. <i>Seminars in Colon and Rectal Surgery</i> , 2006, 17, 55-60.	0.3	1
354	Hypothalamic-Pituitary-Gut Axis Dysregulation in Irritable Bowel Syndrome: Plasma Cytokines as a Potential Biomarker?. <i>Gastroenterology</i> , 2006, 130, 304-311.	1.3	544
355	Efficacy of an Encapsulated Probiotic <i>Bifidobacterium infantis</i> 35624 in Women with Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2006, 101, 1581-1590.	0.4	739
356	Medicine in the Age of "Ulysses": James Joyce's portrait of life, medicine, and disease on a Dublin day a century ago. <i>Perspectives in Biology and Medicine</i> , 2006, 49, 276-285.	0.5	5
357	Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G839-G845.	3.4	85
358	Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice. <i>Clinical and Experimental Immunology</i> , 2006, 144, 273-280.	2.6	55
359	Altered levels of biochemical indices of bone turnover and bone-related vitamins in patients with Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1007-1016.	3.7	45
360	Functional modulation of human intestinal epithelial cell responses by <i>Bifidobacterium infantis</i> and <i>Lactobacillus salivarius</i> . <i>Immunology</i> , 2006, 118, 202-215.	4.4	248

#	ARTICLE	IF	CITATIONS
361	Determinants of vitamin D status in adult Crohn's disease patients, with particular emphasis on supplemental vitamin D use. <i>European Journal of Clinical Nutrition</i> , 2006, 60, 889-896.	2.9	62
362	The gut flora as a forgotten organ. <i>EMBO Reports</i> , 2006, 7, 688-693.	4.5	2,226
363	Bcl-xL expression in vivo in rheumatoid synovium. <i>Clinical Rheumatology</i> , 2006, 25, 789-793.	2.2	28
364	Fas Ligand Promotes Tumor Immune Evasion of Colon Cancer In Vivo. <i>Cell Cycle</i> , 2006, 5, 246-249.	2.6	38
365	Fas ligand expression in human and mouse cancer cell lines; a caveat on over-reliance on mRNA data. <i>Journal of Carcinogenesis</i> , 2006, 5, 5.	2.5	16
366	Multireplicon genome architecture of <i>Lactobacillus salivarius</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 6718-6723.	7.1	216
367	Culture-Independent Analyses of Temporal Variation of the Dominant Fecal Microbiota and Targeted Bacterial Subgroups in Crohn's Disease. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3980-3988.	3.9	277
368	Response to Dr. Kuenstner: More About MAP. <i>American Journal of Gastroenterology</i> , 2006, 101, 1158-1158.	0.4	0
369	Viral load change and sequential evolution of entire hepatitis C virus genome in Irish recipients of single source-contaminated anti-D immunoglobulin*. <i>Journal of Viral Hepatitis</i> , 2005, 12, 594-603.	2.0	10
370	Seasonality of vitamin D status and bone turnover in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1073-1083.	3.7	84
371	A strategy for obtaining near full-length HCV cDNA clones (assemblicons) by assembly PCR. <i>Journal of Virological Methods</i> , 2005, 123, 115-124.	2.1	4
372	Correlation of probiotic <i>Lactobacillus salivarius</i> growth phase with its cell wall-associated proteome. <i>FEMS Microbiology Letters</i> , 2005, 252, 153-159.	1.8	50
373	CD38 is associated with premenopausal and postmenopausal bone mineral density and postmenopausal bone loss. <i>Journal of Bone and Mineral Metabolism</i> , 2005, 24, 28-35.	2.7	20
374	Probiotics: An Emerging Therapy. <i>Current Pharmaceutical Design</i> , 2005, 11, 3-10.	1.9	72
375	The Mycobacteria Story in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2005, 100, 1537-1538.	0.4	61
376	IgG-Mediated Food Intolerance in Irritable Bowel Syndrome: A Real Phenomenon or an Epiphenomenon?. <i>American Journal of Gastroenterology</i> , 2005, 100, 1558-1559.	0.4	22
377	Addressing the "Fas Counterattack" Controversy: Blocking Fas Ligand Expression Suppresses Tumor Immune Evasion of Colon Cancer <i>In vivo</i> . <i>Cancer Research</i> , 2005, 65, 9817-9823.	0.9	83
378	Targeting the Fas/Fas ligand pathway in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2005, 9, 1031-1044.	3.4	47

#	ARTICLE	IF	CITATIONS
379	Physiological Basis for Novel Drug Therapies Used to Treat the Inflammatory Bowel Diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 288, G417-G421.	3.4	70
380	Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. <i>Gastroenterology</i> , 2005, 128, 541-551.	1.3	1,276
381	Acromegaly and Colorectal Cancer: A Comprehensive Review of Epidemiology, Biological Mechanisms, and Clinical Implications. <i>Hormone and Metabolic Research</i> , 2004, 36, 70-71.	1.5	3
382	Synbiotics and colon cancer. , 2004, , 524-580.		1
383	Probiotics and the Immune Response: How Much Can We Expect?. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2004, 39, S748-S749.	1.8	8
384	CON: Surveillance for Ulcerative Colitis-Associated Cancer: Time to Change the Endoscopy and the Microscopy. <i>American Journal of Gastroenterology</i> , 2004, 99, 1633-1636.	0.4	12
385	Celiac Disease and the Transition from Childhood to Adulthood: A 28-Year Follow-Up. <i>American Journal of Gastroenterology</i> , 2004, 99, 2437-2441.	0.4	76
386	Thromboembolism-an Important Manifestation of Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2004, 99, 1971-1973.	0.4	58
387	Vitamin K Status in Patients with Crohn's Disease and Relationship to Bone Turnover. <i>American Journal of Gastroenterology</i> , 2004, 99, 2178-2185.	0.4	71
388	Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. <i>Gut</i> , 2004, 53, 694-700.	12.1	170
389	Substance P and other neuropeptides do not induce mediator release in isolated human intestinal mast cells. <i>Neurogastroenterology and Motility</i> , 2004, 16, 185-193.	3.0	70
390	Host-Flora Interactions in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2004, 10, S16-S24.	1.9	59
391	Antibiotics as a First-line Therapy for Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 324-326.	1.9	6
392	Probiotics in inflammatory bowel disease—therapeutic rationale and role. <i>Advanced Drug Delivery Reviews</i> , 2004, 56, 809-818.	13.7	103
393	Do Taq-generated RT-PCR products from RNA viruses accurately reflect viral genetic heterogeneity?. <i>Journal of Viral Hepatitis</i> , 2004, 11, 108-114.	2.0	16
394	The role of substance P in inflammatory disease. <i>Journal of Cellular Physiology</i> , 2004, 201, 167-180.	4.1	658
395	Mechanisms of adherence of a probiotic Lactobacillus strain during and after in vivo assessment in ulcerative colitis patients. <i>Microbial Ecology in Health and Disease</i> , 2004, 16, 96-104.	3.5	19
396	Making microbes work for mankind—clever trick or a glimpse of the future for IBD treatment?. <i>Gastroenterology</i> , 2004, 127, 667-668.	1.3	7

#	ARTICLE	IF	CITATIONS
397	Clinical Examination of the Gastrointestinal System in the 21st Century-Is the Emphasis Right?. American Journal of Gastroenterology, 2004, 99, 1874-1875.	0.4	1
398	Bacterial DNA within Granulomas of Patients with Crohn's Disease-Detection by Laser Capture Microdissection and PCR. American Journal of Gastroenterology, 2004, 99, 1539-1543.	0.4	161
399	Persistence of hepatitis C virus in a white population: Associations with human leukocyte antigen class I. Human Immunology, 2004, 65, 745-751.	2.4	36
400	Prevalence of bone marrow micrometastases in esophagogastric cancer patients with and without neoadjuvant chemoradiotherapy. Journal of Surgical Research, 2004, 117, 121-126.	1.6	29
401	Probiotics in inflammatory bowel disease. , 2004, , 708-725.		0
402	Upregulation of neurokinin-1 receptor expression in the lungs of patients with sarcoidosis. Journal of Clinical Immunology, 2003, 23, 425-435.	3.8	8
403	Manipulation of the bacterial flora in inflammatory bowel disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 47-61.	2.4	48
404	Suggestive Linkage of 2p22-25 and 11q12-13 with Low Bone Mineral Density at the Lumbar Spine in the Irish Population. Calcified Tissue International, 2003, 72, 651-658.	3.1	39
405	Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo. International Journal of Cancer, 2003, 107, 209-214.	5.1	25
406	Neurokinin-1 receptor (NK-1R) expression is induced in human colonic epithelial cells by proinflammatory cytokines and mediates proliferation in response to substance P. Journal of Cellular Physiology, 2003, 197, 30-41.	4.1	45
407	Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 725-740.	2.4	141
408	Oral immune tolerance to tumor specific antigens may confer growth advantage to esophageal and gastric cancers*. Ecological Management and Restoration, 2003, 16, 218-223.	0.4	8
409	Review article: colitis-associated cancer - time for new strategies. Alimentary Pharmacology and Therapeutics, 2003, 18, 6-9.	3.7	20
410	The prophylactic use of a proton pump inhibitor before food and alcohol. Alimentary Pharmacology and Therapeutics, 2003, 17, 683-686.	3.7	15
411	Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF- β 2 expression. British Journal of Cancer, 2003, 89, 1345-1351.	6.4	43
412	Association of NOD2 with Crohn's Disease in a homogenous Irish population. European Journal of Human Genetics, 2003, 11, 237-244.	2.8	76
413	Effective therapy for advanced gastrointestinal stromal tumors. Gastroenterology, 2003, 124, 1151-1153.	1.3	0
414	Screening for asymptomatic celiac disease among patients referred for bone densitometry measurement. Bone, 2003, 33, 970-974.	2.9	31

#	ARTICLE	IF	CITATIONS
415	Bacterial DNA within granulomas of patients with Crohn's disease-detection by laser capture microdissection and PCR. <i>Gastroenterology</i> , 2003, 124, A500.	1.3	3
416	The therapeutic use of probiotics in gastrointestinal inflammation. , 2003, , 169-184.		0
417	Probiotics: A Perspective on Problems and Pitfalls. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 34-36.	1.5	40
418	Exploring the Iceberg-the Spectrum of Celiac Disease. <i>American Journal of Gastroenterology</i> , 2003, 98, 518-520.	0.4	17
419	Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. <i>Gut</i> , 2003, 52, 975-980.	12.1	399
420	Is nutrition an aetiological factor for inflammatory bowel disease?. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 607-613.	1.6	82
421	Acromegaly and Colorectal Cancer: A Comprehensive Review of Epidemiology, Biological Mechanisms, and Clinical Implications. <i>Hormone and Metabolic Research</i> , 2003, 35, 712-725.	1.5	101
422	Role of antibiotics and probiotics in the management of inflammatory bowel disease. , 2003, , 573-585.		0
423	Role of antibiotics and probiotics in the management of inflammatory bowel disease. , 2003, , 573-585.		0
424	Probiotics and inflammatory bowel disease: from fads and fantasy to facts and future. <i>British Journal of Nutrition</i> , 2002, 88, s5-s9.	2.3	62
425	RT-PCR for the Assessment of Genetically Heterogenous Populations of the Hepatitis C Virus. , 2002, 193, 171-188.		1
426	<i>Mycobacterium paratuberculosis</i> Detected by Nested PCR in Intestinal Granulomas Isolated by LCM in Cases of Crohn's Disease. , 2002, 193, 205-211.		10
427	Genotoxicity of Fecal Water in a Free-Living Irish Population. <i>Nutrition and Cancer</i> , 2002, 42, 62-69.	2.0	11
428	PCR detection of <i>Mycobacterium paratuberculosis</i> in Crohn's disease granulomas isolated by laser capture microdissection. <i>Gut</i> , 2002, 51, 665-670.	12.1	111
429	A Randomised Controlled Trial of a Probiotic <i>Lactobacillus</i> Strain in Healthy Adults: Assessment of its Delivery, Transit and Influence on Microbial Flora and Enteric Immunity. <i>Microbial Ecology in Health and Disease</i> , 2002, 14, 81-89.	3.5	42
430	Role of probiotics in the treatment of intestinal infections and inflammation. <i>Current Opinion in Gastroenterology</i> , 2002, 18, 40-45.	2.3	22
431	Soluble interleukin 2 receptor levels in families of people with schizophrenia. <i>Schizophrenia Research</i> , 2002, 56, 235-239.	2.0	28
432	Viral discrimination and subversion of host defense at the epithelial gateway. <i>Gastroenterology</i> , 2002, 123, 947-948.	1.3	0

#	ARTICLE	IF	CITATIONS
433	Celiac disease and irritable bowel-type symptoms. American Journal of Gastroenterology, 2002, 97, 1463-1467.	0.4	129
434	Nested RT-PCR: Sensitivity Controls are Essential to Determine the Biological Significance of Detected mRNA. , 2002, 193, 065-079.		10
435	Crohn's disease. Lancet, The, 2002, 359, 62-69.	13.7	467
436	The survival and colonic adhesion of Bifidobacterium infantis in patients with ulcerative colitis. International Dairy Journal, 2002, 12, 197-200.	3.0	30
437	Infliximab Therapy for Complicated Sarcoidosis. Annals of Internal Medicine, 2002, 137, 296.	3.9	8
438	Coeliac disease and autoimmune Addison's disease: a clinical pitfall. QJM - Monthly Journal of the Association of Physicians, 2002, 95, 79-82.	0.5	67
439	A search for Mycobacterium paratuberculosis by PCR in Crohn's granulomas isolated by laser capture microdissection. Irish Journal of Medical Science, 2002, 171, 43-43.	1.5	0
440	The prevalence of coeliac disease among female subjects having bone densitometry. Irish Journal of Medical Science, 2002, 171, 145-147.	1.5	11
441	Food allergies. Current Gastroenterology Reports, 2002, 4, 373-382.	2.5	14
442	Investigation of the Genetic Influence of the OPG, VDR (Fok1), and COLIA1 Sp1 Polymorphisms on BMD in the Irish Population. Calcified Tissue International, 2002, 71, 26-35.	3.1	67
443	Sulfate-Reducing Bacteria Colonize Pouches Formed for Ulcerative Colitis but Not for Familial Adenomatous Polyposis. Diseases of the Colon and Rectum, 2002, 45, 384-388.	1.3	117
444	Biological behaviour and clinical implications of micrometastases. British Journal of Surgery, 2002, 87, 1629-1639.	0.3	72
445	Activation of the p38 MAPK and ERK1/2 Pathways Is Required for Fas-Induced IL-8 Production in Colonic Epithelial Cells. Annals of the New York Academy of Sciences, 2002, 973, 161-165.	3.8	18
446	Type I Insulin-like Growth Factor Receptor Expression on Colorectal Adenocarcinoma Cell Lines Is Decreased in Response to the Chemopreventive Agent N-Acetylcysteine. Annals of the New York Academy of Sciences, 2002, 973, 555-558.	3.8	9
447	The host-microbe interface within the gut. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2002, 16, 915-931.	2.4	231
448	The Fas-FasL system and colorectal tumours. Journal of Clinical Pathology, 2002, 55, 559-559.	2.0	2
449	Gut flora in gastrointestinal disease. The European Journal of Surgery Supplement: = Acta Chirurgica Supplement, 2002, , 47-52.	0.2	5
450	Inflammatory bowel disease: Immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology, 2001, 120, 622-635.	1.3	315

#	ARTICLE	IF	CITATIONS
451	Soluble interleukin 2 receptor levels in acute and stable schizophrenia. <i>Schizophrenia Research</i> , 2001, 52, 143-144.	2.0	6
452	Turbo probiotics for IBD. <i>Gastroenterology</i> , 2001, 120, 1297-1303.	1.3	14
453	Mutant Salmonella as vectors for gene therapy. <i>Gastroenterology</i> , 2001, 121, 224-226.	1.3	3
454	Upregulation of Fas-Fas-L (CD95/CD95L)-Mediated Epithelial Apoptosis—A Putative Role in Pouchitis?. <i>Journal of Surgical Research</i> , 2001, 98, 27-32.	1.6	20
455	p53 at the crossroads of colitis and cancer. <i>Gastroenterology</i> , 2001, 120, 1877-1878.	1.3	3
456	Strategy for the maximization of clinically relevant information from hepatitis C virus, RT-PCR quantification. <i>Journal of Clinical Virology</i> , 2001, 20, 163-171.	3.1	3
457	Relation between colitis and colon cancer. <i>Lancet</i> , The, 2001, 357, 246-247.	13.7	28
458	Why is Celiac Disease So Common in Ireland?. <i>Perspectives in Biology and Medicine</i> , 2001, 44, 342-352.	0.5	23
459	In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. <i>American Journal of Clinical Nutrition</i> , 2001, 73, 386s-392s.	4.7	667
460	Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1219-1225.	3.7	255
461	Inferred Hepatitis C Virus Quasispecies Diversity Is Influenced by Choice of DNA Polymerase in Reverse Transcriptase-Polymerase Chain Reactions. <i>Analytical Biochemistry</i> , 2001, 289, 137-146.	2.4	22
462	HLA class II genes determine the natural variance of hepatitis C viral load. <i>Hepatology</i> , 2001, 33, 224-230.	7.3	50
463	Immune privilege or inflammation? Insights into the Fas ligand enigma. <i>Nature Medicine</i> , 2001, 7, 271-274.	30.7	152
464	Tumour necrosis factor α promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families. <i>Genes and Immunity</i> , 2001, 2, 82-87.	4.1	83
465	Probiotics in inflammatory bowel disease. <i>Gut</i> , 2001, 48, 609-609.	12.1	56
466	Fas ligand upregulation is an early event in colonic carcinogenesis. <i>Journal of Clinical Pathology</i> , 2001, 54, 598-604.	2.0	47
467	Response to Dr. Gonzalez Cueto. <i>American Journal of Gastroenterology</i> , 2001, 96, 2794-2795.	0.4	1
468	Anemia in patients with chronic inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 2296-2298.	0.4	63

#	ARTICLE	IF	CITATIONS
469	Tissue viral load variability in chronic hepatitis C. American Journal of Gastroenterology, 2001, 96, 3384-3389.	0.4	33
470	Constitutive ERK1/2 Activation in Esophagogastric Rib Bone Marrow Micrometastatic Cells Is MEK-independent. Journal of Biological Chemistry, 2001, 276, 15537-15546.	3.4	43
471	Diagnosis and Implications of Bone Marrow Micrometastases. , 2001, , 307-315.		0
472	Alteration in the Ratio of cMyc to Mutant p53 is a Phenotypic Trait of Epithelial Cells Committed to Die by Apoptosis. Biochemical Society Transactions, 2000, 28, A29-A29.	3.4	0
473	Anti-TNF Therapy for Crohn's Disease: A Perspective (Infliximab Is Not the Drug We Have Been Waiting) Tj ETQq 1.1 0.784314 rgBT 12	1.9	12
474	Probiotics and Inflammatory Bowel Disease: Is There a Scientific Rationale?. Inflammatory Bowel Diseases, 2000, 6, 107-115.	1.9	147
475	Bone marrow micrometastases in patients with brain metastases from epithelial cell tumours. QJM - Monthly Journal of the Association of Physicians, 2000, 93, 611-615.	0.5	2
476	Interferon- γ sensitizes colonic epithelial cell lines to physiological and therapeutic inducers of colonocyte apoptosis. Journal of Cellular Physiology, 2000, 185, 331-338.	4.1	57
477	Natural fluctuations of hepatitis C viral load in a homogeneous patient population: A prospective study. Hepatology, 2000, 31, 225-229.	7.3	50
478	Viral clearance in hepatitis C (1b) infection: Relationship with human leukocyte antigen class II in a homogeneous population. Hepatology, 2000, 31, 1334-1337.	7.3	65
479	Functional foods and probiotics: Time for gastroenterologists to embrace the concept. Current Gastroenterology Reports, 2000, 2, 345-346.	2.5	14
480	V. Mechanisms of immunologic sensation of intestinal contents. American Journal of Physiology - Renal Physiology, 2000, 278, G191-G196.	3.4	42
481	Colorectal cancer: still a major killer despite progress on many fronts. QJM - Monthly Journal of the Association of Physicians, 2000, 93, 131-134.	0.5	3
482	Differential Expression of Neurokinin-1 Receptor by Human Mucosal and Peripheral Lymphoid Cells. Vaccine Journal, 2000, 7, 371-376.	2.6	40
483	The Inflammatory Response Within Dukes' B Colorectal Cancers: Implications for Progression of Micrometastases and Patient Survival. American Journal of Gastroenterology, 2000, 95, 3607-3614.	0.4	46
484	Bone Marrow Micrometastases and Gastrointestinal Cancer Detection and Significance. American Journal of Gastroenterology, 2000, 95, 1644-1651.	0.4	20
485	Pregnancy and pregnancy outcome in hepatitis C type 1b. QJM - Monthly Journal of the Association of Physicians, 2000, 93, 597-601.	0.5	53
486	<i>Helicobacter pylori</i> Modulates Lymphoepithelial Cell Interactions Leading to Epithelial Cell Damage through Fas/Fas Ligand Interactions. Infection and Immunity, 2000, 68, 4303-4311.	2.2	97

#	ARTICLE	IF	CITATIONS
487	Immunological and genetic links in Crohn's disease. <i>Gut</i> , 2000, 46, 6-7.	12.1	10
488	Neurokinin-1 receptor expression in inflammatory bowel disease: molecular quantitation and localisation. <i>Gut</i> , 2000, 47, 387-396.	12.1	121
489	Esophagogastric cancer-time to change the paradigm. <i>American Journal of Gastroenterology</i> , 2000, 95, 2153-2154.	0.4	2
490	IMMUNOLOGY: Therapeutic Manipulation of Gut Flora. <i>Science</i> , 2000, 289, 1311-1312.	12.6	95
491	The stress response and the hypothalamic-pituitary-adrenal axis: from molecule to melancholia. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2000, 93, 323-333.	0.5	307
492	Gene therapy for food allergy. <i>Gastroenterology</i> , 2000, 119, 269-270.	1.3	3
493	How do intestinal T cells sense the dietary and microbial environment?. <i>Gastroenterology</i> , 2000, 118, 444-446.	1.3	2
494	Turning on "Cell death and turning off Crohn's disease. <i>Gastroenterology</i> , 2000, 119, 1166-1168.	1.3	5
495	Altered Mechanisms of Apoptosis in Colon Cancer: Fas Resistance and Counterattack in the Tumor-Immune Conflict. <i>Annals of the New York Academy of Sciences</i> , 2000, 910, 178-195.	3.8	91
496	Interferon- β sensitizes colonic epithelial cell lines to physiological and therapeutic inducers of colonocyte apoptosis. , 2000, 185, 331.		1
497	BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. <i>Cancer Research</i> , 2000, 60, 6171-7.	0.9	283
498	Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. <i>Gut</i> , 1999, 44, 156-162.	12.1	123
499	An International Survey of The Use and Attitudes Regarding Alternative Medicine by Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 1999, 94, 1298-1303.	0.4	117
500	The Fas counterattack: cancer as a site of immune privilege. <i>Trends in Immunology</i> , 1999, 20, 46-52.	7.5	218
501	Fas ligand and Fas receptor are coexpressed in normal human esophageal epithelium: a potential mechanism of apoptotic epithelial turnover. <i>Ecological Management and Restoration</i> , 1999, 12, 90-98.	0.4	21
502	Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack. <i>Ecological Management and Restoration</i> , 1999, 12, 83-89.	0.4	29
503	Type 1 diabetes mellitus, coeliac disease, and lymphoma: a report of four cases. <i>Diabetic Medicine</i> , 1999, 16, 614-617.	2.3	35
504	Fas counter-attack "the best form of tumor defense?. <i>Nature Medicine</i> , 1999, 5, 267-268.	30.7	74

#	ARTICLE	IF	CITATIONS
505	Title is missing!. <i>Antonie Van Leeuwenhoek</i> , 1999, 76, 279-292.	1.7	320
506	Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor. <i>Clinical and Experimental Metastasis</i> , 1999, 17, 87-95.	3.3	14
507	Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. <i>Hepatology</i> , 1999, 29, 904-907.	7.3	91
508	Probiotics: towards demonstrating efficacy. <i>Trends in Food Science and Technology</i> , 1999, 10, 393-399.	15.1	80
509	Glial cells, mucosal integrity, and inflammatory bowel disease. <i>Gastroenterology</i> , 1999, 116, 493-494.	1.3	3
510	Micrometastases in esophagogastric cancer: High detection rate in resected rib segments. <i>Gastroenterology</i> , 1999, 116, 543-548.	1.3	169
511	Thrombosis, factor V Leiden, and inflammatory bowel disease. <i>Gastroenterology</i> , 1999, 116, 778-779.	1.3	1
512	Setback for systemic therapy of esophageal cancer: Right concept, disappointing result. <i>Gastroenterology</i> , 1999, 117, 1020-1021.	1.3	4
513	Escape from the Smad world by colon cancer. <i>Gastroenterology</i> , 1999, 116, 1496-1497.	1.3	2
514	Intestinal Lymphoepithelial Communication. <i>Advances in Experimental Medicine and Biology</i> , 1999, 473, 1-9.	1.6	19
515	The gastrointestinal system and psychological factors. <i>Current Opinion in Psychiatry</i> , 1999, 12, 739-742.	6.3	2
516	Expression of Fas (CD95/APO-1) Ligand by Human Breast Cancers: Significance for Tumor Immune Privilege. <i>Vaccine Journal</i> , 1999, 6, 457-463.	2.6	46
517	Genetic analysis of the 3' untranslated region of the tumour necrosis factor shows a highly conserved region in rheumatoid arthritis affected and unaffected subjects. <i>Journal of Medical Genetics</i> , 1999, 36, 214-6.	3.2	12
518	Brain-gut axis and mucosal immunity: a perspective on mucosal psychoneuroimmunology. <i>Seminars in Gastrointestinal Disease</i> , 1999, 10, 8-13.	0.8	32
519	Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. <i>Antonie Van Leeuwenhoek</i> , 1999, 76, 279-92.	1.7	93
520	Neuroimmunomodulation in Inflammatory Bowel Disease: How Far from "Bench" to "Bedside"? <i>Annals of the New York Academy of Sciences</i> , 1998, 840, 723-734.	3.8	32
521	Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. , 1998, 186, 240-246.		112
522	Modelling the major histocompatibility complex susceptibility to RA using the MASC method. , 1998, 15, 419-430.		24

#	ARTICLE	IF	CITATIONS
523	Irish society of gastroenterology. Irish Journal of Medical Science, 1998, 167, 2-22.	1.5	0
524	National scientific medical meeting 1997 abstracts. Irish Journal of Medical Science, 1998, 167, 1-44.	1.5	0
525	Waterford surgical October club and surgical section, Royal Academy of Medicine Joint Surgical Symposium. Irish Journal of Medical Science, 1998, 167, 64-67.	1.5	0
526	Irish society of gastroenterology. Irish Journal of Medical Science, 1998, 167, 2-23.	1.5	0
527	Immuno-epithelial interactions: Cytokine modulation of normal rabbit colonocyte function. In Vitro Cellular and Developmental Biology - Animal, 1998, 34, 743-746.	1.5	1
528	Enteric neuropathophysiology and inflammatory bowel disease. Neurogastroenterology and Motility, 1998, 10, 185-187.	3.0	25
529	Genes, bacteria, and T cells: Ingredients for inflammatory bowel disease. Gastroenterology, 1998, 115, 1595-1596.	1.3	10
530	Intestinal graft-versus-host disease. Gastroenterology, 1998, 115, 220-222.	1.3	3
531	Enteropathogenic E. coli: Intimacy redefined. Gastroenterology, 1998, 115, 233-234.	1.3	0
532	A significant step in the celiac puzzle. Gastroenterology, 1998, 114, 1339-1340.	1.3	3
533	Cytokine induced expression of substance P (NK-1) receptors in human colonic epithelial cells. Gastroenterology, 1998, 114, A373.	1.3	1
534	Fas ligand expression by normal human esophageal squamous epithelium: Another site of immune privilege. Gastroenterology, 1998, 114, A929.	1.3	4
535	Increased soluble interleukin 2 receptor levels in schizophrenia. Schizophrenia Research, 1998, 29, 263-267.	2.0	37
536	Quantitative Measurement of mRNA Expression by Competitive RT-PCR. , 1998, 92, 183-194.		17
537	IMMUNOLOGICAL TESTS TO MONITOR INFLAMMATORY BOWEL DISEASE“HAVE THEY DELIVERED YET?. American Journal of Gastroenterology, 1998, 93, 295-297.	0.4	7
538	Mucosal subepithelial binding sites for the bacterial chemotactic peptide, formyl-methionyl-leucyl-phenylalanine (FMLP). Gut, 1998, 42, 374-379.	12.1	37
539	Coeliac disease and epilepsy. QJM - Monthly Journal of the Association of Physicians, 1998, 91, 303-308.	0.5	81
540	Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. Journal of Pathology, 1998, 186, 240-246.	4.5	3

#	ARTICLE	IF	CITATIONS
541	The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. <i>Journal of Immunology</i> , 1998, 160, 5669-75.	0.8	219
542	Substance P (neurokinin-1) receptor is a marker of human mucosal but not peripheral mononuclear cells: molecular quantitation and localization. <i>Journal of Immunology</i> , 1998, 161, 2232-40.	0.8	51
543	Antibody 'markers' in Crohn's disease: opportunity or overstatement?. <i>Gut</i> , 1997, 40, 557-558.	12.1	19
544	Histological patchiness and sparing of the rectum in ulcerative colitis: refuting the dogma.. <i>Journal of Clinical Pathology</i> , 1997, 50, 354-355.	2.0	10
545	Micrometastases: marker of metastatic potential or evidence of residual disease?. <i>Gut</i> , 1997, 40, 512-515.	12.1	100
546	Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1997, 90, 183-188.	0.5	190
547	Mucosal Substance P Receptor Expression in HIV Infection and Inflammatory Bowel Disease. <i>NeuroImmunoModulation</i> , 1997, 4, 70-76.	1.8	12
548	Innate resistance to <i>Listeria monocytogenes</i> in tumor-bearing mice. <i>Journal of Leukocyte Biology</i> , 1997, 62, 726-732.	3.3	1
549	Designer drugs for inflammatory bowel disease. <i>Gastroenterology</i> , 1997, 112, 2153-2154.	1.3	2
550	Quantification of the placebo response in ulcerative colitis. <i>Gastroenterology</i> , 1997, 112, 1854-1858.	1.3	123
551	A Gut Reaction—Lymphoepithelial Communication in the Intestine. <i>Science</i> , 1997, 275, 1897-0.	12.6	28
552	Insulin-dependent diabetes mellitus and coeliac disease. <i>Lancet, The</i> , 1997, 349, 1096-1097.	13.7	201
553	Progress in treating esophageal adenocarcinoma. <i>Gastroenterology</i> , 1997, 112, 1417-1418.	1.3	13
554	The Fas Counterattack: A Molecular Mechanism of Tumor Immune Privilege. <i>Molecular Medicine</i> , 1997, 3, 294-300.	4.4	53
555	The Fas counterattack: a molecular mechanism of tumor immune privilege. <i>Molecular Medicine</i> , 1997, 3, 294-300.	4.4	15
556	High prevalence of celiac disease among patients with insulin-dependent (type I) diabetes mellitus. <i>American Journal of Gastroenterology</i> , 1997, 92, 2210-2.	0.4	80
557	The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.. <i>Journal of Experimental Medicine</i> , 1996, 184, 1075-1082.	8.5	840
558	Appropriateness of laboratory tests: Requests for atypical pneumonia serology in a teaching hospital. <i>Irish Journal of Medical Science</i> , 1996, 165, 93-94.	1.5	2

#	ARTICLE	IF	CITATIONS
559	A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , 1996, 10, 777-786.	3.7	142
560	Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. <i>American Journal of Human Genetics</i> , 1996, 59, 676-83.	6.2	129
561	Critical appraisal of enteral nutrition as primary therapy in adults with Crohn's disease. <i>American Journal of Gastroenterology</i> , 1996, 91, 2075-9.	0.4	10
562	Regional immunosuppression in esophageal squamous cancer: evidence from functional studies with matched lymph nodes. <i>Journal of Immunology</i> , 1996, 157, 4717-20.	0.8	28
563	Discontent with Dysplasia Surveillance in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 1995, 1, 80-83.	1.9	6
564	Irish society for rheumatology Proceedings of Annual General Meeting held 14th October, 1994 at St. James's Hospital, Dublin 8. <i>Irish Journal of Medical Science</i> , 1995, 164, 89-99.	1.5	0
565	Non-linkage of a T-Cell Receptor β Chain Microsatellite (D7S485) to Rheumatoid Arthritis in Multiplex Families. <i>Journal of Autoimmunity</i> , 1995, 8, 131-138.	6.5	2
566	Micrometastases in bone marrow of patients undergoing "curative" surgery for gastrointestinal cancer. <i>Gastroenterology</i> , 1995, 109, 1535-1540.	1.3	54
567	Patchiness of mucosal inflammation in treated ulcerative colitis: A prospective study. <i>Gastrointestinal Endoscopy</i> , 1995, 42, 232-237.	1.0	204
568	Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 250-256.	2.8	187
569	The Brain-Gut Axis and the Mucosal Immunoinflammatory Response. , 1995, , 103-108.		0
570	From basic advances to therapeutic strategies in ulcerative colitis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1995, 88, 599-602.	0.5	0
571	Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. <i>American Journal of Gastroenterology</i> , 1995, 90, 2106-14.	0.4	113
572	A prospective comparison of laparoscopy and imaging in the staging of esophagogastric cancer before surgery. <i>American Journal of Gastroenterology</i> , 1995, 90, 2191-4.	0.4	51
573	Discontent with dysplasia surveillance in ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 1995, 1, 80-3.	1.9	1
574	Immunospressive Agents in Inflammatory Bowel Disease: Current Status and Future Prospects. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 1994, 8, 383-387.	1.7	0
575	Current concepts of the pathogenesis of inflammatory bowel disease. <i>Irish Journal of Medical Science</i> , 1994, 163, 544-549.	1.5	14
576	Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity. <i>Digestive Diseases and Sciences</i> , 1994, 39, 1638-1641.	2.3	35

#	ARTICLE	IF	CITATIONS
577	Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?. <i>Lancet, The</i> , 1994, 343, 71-74.	13.7	587
578	Neutrophil autoantibodies in inflammatory Bowel disease: Are they important?. <i>Gastroenterology</i> , 1994, 107, 586-589.	1.3	34
579	Gene-targeted immunologic knockouts: New models of inflammatory bowel disease. <i>Gastroenterology</i> , 1994, 107, 312-314.	1.3	9
580	Chapter 26 Neurotransmitters and cytokines in CNS pathology. <i>Progress in Brain Research</i> , 1994, 103, 319-330.	1.4	27
581	Immunosuppressive agents in IBD: current status and future prospects. , 1994, , 367-373.		0
582	Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews.. <i>Gut</i> , 1993, 34, 517-524.	12.1	314
583	Pathogenesis of ulcerative colitis. <i>Lancet, The</i> , 1993, 342, 407-411.	13.7	91
584	Vip Modulates Intracellular Calcium Oscillations in Human Lymphoblasts. <i>Immunopharmacology and Immunotoxicology</i> , 1993, 15, 429-446.	2.4	5
585	Odd forms of inflammatory bowel disease: What can they tell us?. <i>Gastroenterology</i> , 1993, 104, 327-329.	1.3	14
586	Distinct associations of HLA Class II genes with inflammatory bowel disease. <i>Gastroenterology</i> , 1993, 104, 741-748.	1.3	263
587	Immunosuppressive and Immunomodulatory Therapy for Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 1993, 7, 115-120.	1.7	3
588	Biotinylated Neuropeptide Analogs: Design and Use as Probes for Target Cells in Heterogeneous Populations. <i>Methods in Neurosciences</i> , 1993, , 76-90.	0.5	0
589	Successful combined liver and small intestine transplantation for short-gut syndrome and liver failure. <i>Western Journal of Medicine</i> , 1993, 158, 184-8.	0.3	8
590	Medical Treatment of Inflammatory Bowel Disease. <i>Annual Review of Medicine</i> , 1992, 43, 125-133.	12.2	27
591	Interleukin 8, neutrophils, and acute inflammation. <i>Gastroenterology</i> , 1992, 103, 341-343.	1.3	4
592	Neutrophil autoantibodies in ulcerative colitis: Familial aggregation and genetic heterogeneity. <i>Gastroenterology</i> , 1992, 103, 456-461.	1.3	183
593	Ulcerative colitis-linked antineutrophil cytoplasmic antibody in the cotton-top tamarin model of colitis. <i>Gastroenterology</i> , 1992, 102, 1493-1498.	1.3	20
594	The role of autoantibodies and autoimmunity in chronic inflammatory disorders of the gut. <i>Current Opinion in Gastroenterology</i> , 1992, 8, 988-992.	2.3	8

#	ARTICLE	IF	CITATIONS
595	Biotinylation of a bombesin/gastrin-releasing peptide analogue for use as a receptor probe. <i>Peptides</i> , 1991, 12, 375-381.	2.4	11
596	Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. <i>Gastroenterology</i> , 1991, 100, 1590-1596.	1.3	292
597	Oral Mesalamine (Asacol) for Mildly to Moderately Active Ulcerative Colitis. <i>Annals of Internal Medicine</i> , 1991, 115, 350-355.	3.9	196
598	Neutrophil Cytoplasmic Antibodies: A Link Between Primary Sclerosing Cholangitis and Ulcerative Colitis. <i>Gastroenterology</i> , 1991, 100, 1385-1391.	1.3	332
599	Role of mucosal T-cell-generated cytokines in epithelial cell injury. <i>Immunologic Research</i> , 1991, 10, 472-478.	2.9	19
600	Neutrophil autoantibodies as disease markers for ulcerative colitis. <i>Immunologic Research</i> , 1991, 10, 479-484.	2.9	16
601	Prevalence and severity of periodontal disease in patients with inflammatory bowel disease. <i>Journal of Clinical Periodontology</i> , 1991, 18, 690-697.	4.9	57
602	Neutrophil cytoplasmic antibodies: A link between primary sclerosing cholangitis and ulcerative colitis. <i>Gastroenterology</i> , 1991, 100, 1385-1391.	1.3	95
603	Colonoscopy during an attack of severe ulcerative colitis. <i>American Journal of Gastroenterology</i> , 1991, 86, 1278.	0.4	5
604	Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. <i>Gastroenterology</i> , 1991, 100, 1385-91.	1.3	76
605	Sulfasalazine inhibits the binding of TNF α to its receptor. <i>Immunopharmacology</i> , 1990, 20, 217-224.	2.0	67
606	A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. <i>Journal of Allergy and Clinical Immunology</i> , 1990, 86, 202-210.	2.9	505
607	Enhanced peripheral blood T-cell cytotoxicity in inflammatory bowel disease. <i>Journal of Clinical Immunology</i> , 1989, 9, 55-64.	3.8	26
608	Increased neutrophil receptors for and response to the proinflammatory bacterial peptide formyl-methionyl-leucyl-phenylalanine in Crohn's disease. <i>Gastroenterology</i> , 1989, 97, 20-28.	1.3	75
609	Immunology of Inflammatory Bowel Disease. , 1989, , 291-310.		3
610	Role of Natural Effector Cells in Human Gastrointestinal Disease. , 1989, , 455-479.		1
611	Enhanced neutrophil chemiluminescence in familial mediterranean fever. <i>Journal of Clinical Immunology</i> , 1988, 8, 148-156.	3.8	25
612	Neuroendocrine modulation of the immune system. <i>Digestive Diseases and Sciences</i> , 1988, 33, 41S-49S.	2.3	86

#	ARTICLE	IF	CITATIONS
613	Role of the CD45 (T-200) molecule in anti-CD3-triggered T cell-mediated cytotoxicity. Cellular Immunology, 1988, 117, 99-110.	3.0	4
614	Hermansky-Pudlak syndrome: an immunologic assessment of 15 cases. American Journal of Medicine, 1988, 85, 823-828.	1.5	43
615	Extending the Scope in Celiac Disease. New England Journal of Medicine, 1988, 319, 782-783.	27.0	19
616	Human mucosal T-cell cytotoxicity. Gastroenterology, 1988, 94, 960-967.	1.3	46
617	Hidradenitis suppurativa. Glucose tolerance, clinical, microbiologic, and immunologic features and HLA frequencies in 27 patients. Archives of Dermatology, 1988, 124, 1043-1046.	1.4	49
618	Human mucosal cytotoxic effector cells. Gastroenterology, 1987, 92, 1951-1957.	1.3	51
619	Immunologic Mechanisms in Intestinal Diseases. Annals of Internal Medicine, 1987, 106, 853.	3.9	80
620	Modulation of ongoing human immunoglobulin synthesis by natural killer cells. Cellular Immunology, 1987, 107, 74-88.	3.0	36
621	Cytotoxic Lymphocytes in Human Intestinal Mucosa. Advances in Experimental Medicine and Biology, 1987, 216A, 457-463.	1.6	0
622	Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization. Journal of Clinical & Laboratory Immunology, 1987, 24, 69-74.	0.1	22
623	Mast Cell Heterogeneity: Effect of Anti-Allergic Compounds on Neuropeptide-Induced Histamine Release. International Archives of Allergy and Immunology, 1986, 80, 424-426.	2.1	19
624	Inhibition of cytotoxicity by sulfasalazine. II. Sulfasalazine and sulfapyridine inhibit different stages of the NK and NKCF lytic processes. Immunopharmacology, 1986, 11, 111-118.	2.0	25
625	Food Allergy and Adverse Reactions. , 1986, , 317-333.		0
626	Functional characterization of mast cells generated in vitro from the mesenteric lymph node of rats infected with Nippostrongylus brasiliensis. Immunology, 1986, 57, 455-9.	4.4	4
627	K562 killing by K, IL 2-responsive NK, and T cells involves different effector cell post-binding trigger mechanisms. Journal of Immunology, 1986, 137, 723-6.	0.8	7
628	Comparative Aspects of Mast Cell Heterogeneity in Different Species and Sites. International Archives of Allergy and Immunology, 1985, 77, 126-129.	2.1	29
629	The pancreas, primary biliary cirrhosis and the dry gland syndrome. Irish Journal of Medical Science, 1985, 154, 387-389.	1.5	1
630	Intestinal mucosal mast cells: isolation from rat lamina propria and purification using unit gravity velocity sedimentation. Immunology, 1985, 55, 721-8.	4.4	37

#	ARTICLE	IF	CITATIONS
631	Mast cell heterogeneity: effects of neuroenteric peptides on histamine release. Journal of Immunology, 1985, 135, 1331-7.	0.8	324
632	Mast cell heterogeneity. Canadian Journal of Physiology and Pharmacology, 1984, 62, 734-737.	1.4	41
633	The influence of endorphins on peritoneal and mucosal mast cell secretion. Journal of Allergy and Clinical Immunology, 1984, 74, 499-504.	2.9	56
634	Endoscopic sphincterotomy. Irish Journal of Medical Science, 1983, 152, 373-376.	1.5	2
635	Mast cell heterogeneity. Monographs in Allergy, 1983, 18, 124-8.	0.2	13
636	Primary Biliary Cirrhosis associated with Coeliac Disease. Irish Medical Journal, 1983, 76, 282.	0.0	7
637	Successful Endoscopic Removal of a Common Bile Duct Foreign Body. Endoscopy, 1982, 14, 26-27.	1.8	9
638	Coeliac disease and diabetes mellitus: a study of 24 patients with HLA typing. The Quarterly Journal of Medicine, 1982, 51, 329-35.	1.0	29
639	Cerebral intravascular coagulation complicating diabetic ketoacidosis. Irish Journal of Medical Science, 1981, 150, 156-157.	1.5	4
640	Hereditary angioedemaâ€”A cause of abdominal pain, often missed?. Irish Journal of Medical Science, 1981, 150, 335-337.	1.5	0
641	Sonolucent Biliary Cast Preventing Endoscopic Sphincterotomy. Endoscopy, 1981, 13, 220-220.	1.8	2
642	Treatment of Oral Crohn's Disease. , 0, , 164-167.		0
643	Steroids in Crohn's: are They Obsolete?. , 0, , 28-31.		1
644	From basic advances to therapeutic strategies in ulcerative colitis. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.5	0
645	Psychological Stress: Something to Worry About?. , 0, , 129-132.		0
646	Making the Most of Methotrexate. , 0, , 51-54.		1
647	Abnormal Liver Testsâ€” What Should we do About Them?. , 0, , 18-20.		0
648	Pathology Reportsâ€” Pitfalls For the Unwary. , 0, , 5-7.		0

#	ARTICLE	IF	CITATIONS
649	Prevention and Treatment of Osteoporosis. , 0, , 201-204.		1
650	Use in Ulcerative Colitis. , 0, , 70-73.		0
651	Pulmonary Manifestations: Rare But Real. , 0, , 213-216.		0
652	NSAIDs and COX-2 Selective Agents: Cause Or Cure of Pain in IBD?. , 0, , 136-138.		0
653	Dealing With Infusion Reactions. , 0, , 67-69.		0
654	Complementary and Alternative Therapy -the Way Forward Or a Step Back?. , 0, , 121-124.		0
655	Surveillance Colonoscopy in Uc: Alternatives and Ways to Improve Outcome. , 0, , 15-17.		0
656	Intestinal Infections: Mimics and Precipitants of Relapse. , 0, , 217-221.		1
657	Refractory Proctitis. , 0, , 156-158.		0
658	Biologic Treatments in IBD. , 0, , 111-115.		0
659	Sclerosing Cholangitisâ€” What to Do?. , 0, , 205-208.		1
660	6-Mercaptopurine Or Azathioprine?. , 0, , 45-47.		1
661	Appendectomy For Ulcerative Colitisâ€” A Therapeutic Option?. , 0, , 108-110.		0
662	TPMT Testing: is it Essential?. , 0, , 40-44.		0
663	Databasesâ€” Are They Worth the Bother?. , 0, , 237-239.		0
664	Drugs to Avoid. , 0, , 133-135.		0
665	Iron Replacementâ€” is it Safe and Effective?. , 0, , 139-141.		0
666	Microscopic Colitis. , 0, , 222-225.		0

#	ARTICLE	IF	CITATIONS
667	Stem Cell Transplantation For IBD. , 0, , 116-120.		0
668	What is the Best Way to Image Perianal Crohn's Disease?. , 0, , 11-14.		0
669	Leukocytapheresis: Filtering Out the Facts. , 0, , 105-107.		0
670	Short Bowel. , 0, , 171-174.		0
671	CMV co-Infectionâ€” Does it Matter?. , 0, , 159-163.		2
672	Nutritional Therapy For Crohn's Disease: is it For Adults?. , 0, , 77-80.		0
673	Pathophysiologic Approach to Treatment of Diarrhea in Crohn's Disease. , 0, , 168-170.		1
674	Is Monitoring Necessary?. , 0, , 21-24.		1
675	Do They Have a Role in Crohn's Disease?. , 0, , 25-27.		1
676	Thromboembolic Disease: An Under-Recognized Complication?. , 0, , 209-212.		0
677	Cyclosporine: Balancing Risk and Benefit. , 0, , 55-58.		0
678	Probioticsâ€” Separating Science From Snakeoil. , 0, , 89-92.		0
679	Smoking and Nicotineâ€” Poison For Crohn's, Potion For Colitis?. , 0, , 96-99.		0
680	What to do with Dysplasia, DALMs, and Adenomas. , 0, , 189-192.		0
681	Trials and Tribulationsâ€” Interpreting Clinical Trials in IBD. , 0, , 81-84.		1
682	Functional Problems. , 0, , 125-128.		0
683	Pregnancy: What Drugs Can we Use?. , 0, , 146-149.		1
684	Colitis-Associated Cancer: What's the Risk to Your Patients?. , 0, , 185-188.		0

#	ARTICLE	IF	CITATIONS
685	Shared Care: Tactical Team Selection. , 0, , 233-236.		0
686	Capsule Endoscopy: Do We Need It?. , 0, , 1-4.		1
687	Geneticsâ€™ Clinical and Therapeutic Applications. , 0, , 85-88.		0
688	Thiopurines: How Long Should we Use Them For?. , 0, , 48-50.		0
689	Predicting Outcome in Severe UC. , 0, , 153-155.		0
690	What is Indeterminate Colitis?. , 0, , 179-181.		2
691	Outpatient Servicesâ€™ Do Doctors Still Have a Role?. , 0, , 229-232.		0
692	How to Prevent Growth Failure in Children. , 0, , 150-152.		1
693	Mycobacterium Aviumparatuberculosis in Crohn's Disease: Player Or Spectator?. , 0, , 36-39.		0
694	Infliximab and Surgery: Health Or Hazard?. , 0, , 74-76.		0
695	Non-Invasive Diagnosis and Assessment. , 0, , 8-10.		0
696	Pouches for Indeterminate Colitis?. , 0, , 182-184.		1
697	Arthritidesâ€™ Helping the Joints Without Harming the Gut. , 0, , 197-200.		0
698	Hepatitis B and C Virusesâ€™ How do They Affect Management of IBD?. , 0, , 142-145.		0
699	How Can we Prevent Tuberculosis?. , 0, , 63-66.		0
700	Worms. , 0, , 93-95.		0
701	Antibiotics: Which, When, and For How Long?. , 0, , 32-35.		0
702	Management of Internal Fistulae. , 0, , 175-178.		0

#	ARTICLE	IF	CITATIONS
703	Diverticular Colitis. , 0, , 226-228.		0
704	Functional Foods and Gastrointestinal Disorders. , 0, , 153-174.		0
705	Gastrointestinal Manifestations of Immunological Disorders. , 0, , 2612-2631.		0
706	Contraindicationsâ€™ Absolute Or Relative?. , 0, , 59-62.		1
707	Cystic Diseases of the Liver and Biliary Tract. , 0, , 361-367.		1
708	Acute Viral Hepatitis. , 0, , 374-386.		1
709	Gastrointestinal Dilation and Stent Placement. , 0, , 643-663.		1
710	Liver: Anatomy, Microscopic Structure, and Cell Types. , 0, , 50-57.		1
711	Probiotics and inflammatory bowel disease: Is there a scientific rationale?. Inflammatory Bowel Diseases, 0, 6, 107-115.	1.9	51
712	Anti-tnf therapy for Crohn's disease: A perspective (infliximab is not the drug we have been waiting) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.9	4
713	Tumors of the Small Intestine. , 0, , 202-207.		0
714	Computed Tomography of the Gastrointestinal Tract. , 0, , 756-767.		0
715	Complications of AIDS and Other Immunodeficiency States. , 0, , 501-508.		0
716	Helminthic Infections of the Gastrointestinal Tract and Liver. , 0, , 524-543.		0
717	Endoscopic Retrograde Cholangiopancreatography: Diagnostic and Therapeutic. , 0, , 634-642.		0
718	Approach to the Patient with Ascites and Its Complications. , 0, , 447-458.		0
719	Obesity: Treatment and Complications. , 0, , 491-494.		0
720	Esophageal Neoplasms. , 0, , 93-101.		0

#	ARTICLE	IF	CITATIONS
721	Gastrointestinal Manifestations of Systemic Diseases. , 0, , 544-553.		0
722	Radiation Injury in the Gastrointestinal Tract. , 0, , 597-602.		0
723	Endoscopic Mucosal Biopsy: Histopathological Interpretation. , 0, , 878-930.		0
724	Dysmotility of the Small Intestine and Colon. , 0, , 149-169.		0
725	Miscellaneous diseases of the small intestine. , 0, , 208-215.		0
726	Diseases of the Peritoneum, Retroperitoneum, Mesentery, and Omentum. , 0, , 484-490.		0
727	Positron Emission Tomography in the Gastrointestinal Tract. , 0, , 782-803.		0
728	Endoscopic Diagnosis and Treatment of Nonvariceal Upper Gastrointestinal hemorrhage. , 0, , 675-679.		0
729	Primary Sclerosing Cholangitis and Other Cholangiopathies. , 0, , 354-360.		0
730	Abdominal Angiography. , 0, , 820-841.		0
731	Gastrointestinal Manifestations of Immunological Disorders. , 0, , 787-792.		0